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Female-controlled preventative technologies are being developed to decrease HIV 
sexual transmission rates in resource poor regions of the world where the pandemic is 
most prevalent. Intravaginal rings (IVRs) comprise extended duration vaginal drug 
delivery vehicles which may provide sustained release of antiretrovirals at local 
inhibitory concentrations to prevent initial HIV infection during coitus. Few IVR 
formulations have been researched for HIV prophylaxis although numerous 
antiretrovirals are excellent candidates. Poor progress is due in part to limitations of 
conventional IVR technology in delivering antiretrovirals with diverse physiochemical 
properties and dosing requirements. Furthermore, there is limited understanding of drug 
vaginal pharmacokinetics and potential toxicological effects on the local environment. 
Consequently, in this dissertation several candidate antiretrovirals were formulated in 
new IVR platforms and animal models were developed to characterize the IVR 
formulations in vivo.  
In the first part of the dissertation, polyurethane IVRs were designed that 
delivered the potent and dual-acting pyrimidinedione congeners for up to one month. The 
pyrimidinediones attained concentrations throughout the nonhuman primate vaginal tract 
that were expected to be inhibitory against HIV, with no observed detrimental effects to 
the vaginal environment. In the second part of the dissertation, an IVR was developed to 
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simultaneously deliver dapivirine and tenofovir which possess contrasting hydrophilicity 
and differing mechanisms of action against HIV. A two segment ring design was utilized 
which independently optimized tenofovir and dapivirine release by using compositionally 
different polyurethanes. In the final two parts of the dissertation, a hydrophilic 
polyurethane reservoir IVR was engineered and tested in a new sheep model, whereby 
tenofovir vaginal concentrations  from the IVR were similar to the clinically effective 
tenofovir vaginal gel but for 90 day duration. The tunable IVR platform allowed for 
achievement of desired drug release rates and ring mechanical stiffness which were time-
independent. No major toxicological effects were observed in sheep, and extensive IVR 
in vitro characterization was performed to ensure that a chemically and physically 
stabilized product was achieved.  
The work reported herein describes the design and characterization of 
antiretroviral-eluting intravaginal rings which each hold promise as preventative 
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1.1 Vaginal Drug Delivery 
Although the medical device and combination drug-device fields are often 
perceived as relatively new, intravaginal insertion of devices and therapeutics have 
existed for centuries with the primary objective of preventing conception (68). 
Intravaginal drug dosing, while less commonly used compared to oral or transdermal 
routes of administration, can offer certain advantages.  Clearly, women-specific local 
indications such as vaginal infections (vaginitis) are excellent candidates for vaginal drug 
delivery. Less known, however, is that many small molecules including hormonal 
compounds demonstrate high vaginal absorption and thus can achieve effective systemic 
concentrations for indications including contraception and hormone replacement therapy 
(HRT) for post-menopausal women. Vaginal drug delivery is also advantageous as it is 
non-invasive, may be self-administered, avoids first-pass hepatic drug metabolism, often 
demonstrates high bioavailability with low fluctuation in systemic concentrations (i.e., 
peaks and troughs), and when intended for local delivery often shows less systemic side 
effects since a significantly lower dose achieves effectiveness (2, 101). Potential 
drawbacks of intravaginal drug delivery will be discussed in greater detail below and 
vary with the type of dosage form, but may include interference with coitus, cultural 
taboos associated with touching of the reproductive anatomy, and undesirable product 
attributes such as excess vaginal wetness or leakage.  
 
 
1.2 HIV and Microbicides 
 
Virtually all currently marketed vaginal drug products are intended to treat or 
prevent unwanted pregnancy, menopausal-related symptoms, and vaginal inflammation 
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due to infection (vaginitis) (100). However, recently there has been considerable effort to 
expand indications including uterine fibroids and cancer, diabetes, and prevention of 
diseases via vaccine or chemoprophylactic delivery – primarily sexually transmitted 
infections including the Human Immunodeficiency Virus (HIV) (3, 8, 28, 34, 40). 
Although HIV infects both men and women, a strong rationale exists for developing HIV 
prophylactic intravaginal dosage forms; 22 of the world’s 33 million HIV-infected 
individuals reside in sub-Saharan Africa, where HIV incidence on average is 1.3 times 
higher in women than men and an even higher disparity is observed with young adults 
aged 15-24 (82). The startlingly high HIV incidence in sub-Saharan African young 
women - up to 20% in some regions (82) - is poorly understood and likely complicated 
by many intertwined biological and social factors (16, 53, 65). Vaccine development has 
been the focal point of efforts to prevent the spread of HIV since it was discovered in the 
early 1980s, yet to-date only one clinical trial has shown any significant protective effect 
against HIV (31). To protect this high risk, sizeable female population against HIV 
sexual transmission in the absence of an efficacious vaccine, women-controlled 
prophylactic vaginal products termed microbicides have been under development for 
approximately two decades (73). 
Thus far, vaginal gel dosage forms have been the only microbicides clinically 
evaluated for HIV prophylactic effectiveness, in part due to their formulation simplicity 
and low production cost. The first microbicide clinical trial was conducted in 2002 with a 
Nonoxynol-9 gel, a nonionic surfactant which has been used for years as a contraceptive 
spermicide and was more recently found to inactivate HIV by disrupting its envelope. 
Although in vitro antiviral results were promising, limited safety data was generated prior 
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to efficacy studies in women, where Nonoxynol-9 exposure increased the rate of HIV 
infection in women who frequently applied the product (84). Similarly, the surfactant 
C31G, composed of alkyl dimethyl glycine and alkyl dimethyl amine oxide, did not 
prevent HIV infection and may have increased the incidence of adverse events in women 
(25, 63). The broad consensus from these early microbicide clinical trials was that these 
surfactants possess relatively low potency against HIV and harm the protective vaginal 
mucosa due to their nonspecific mechanism of action, allowing passage of virus to 
underlying immune cells and/or recruiting susceptible immune cells via an inflammatory 
response. Polyanions were also evaluated for prophylactic HIV effectiveness, but fared 
no better with cellulose sulfate demonstrating more HIV infections in the active versus 
placebo arm (83). Carrageenan-based gels PRO2000 and Carraguard showed no harm but 
were not effective (50, 75). In the Carraguard trial, gel applicators were examined post-
use for evidence of user adherence, and it was discovered that women were not using the 
gel as instructed and were over-reporting adherence which was disturbingly low at 42% 
on average. More recently, the CAPRISA 004 trial evaluated the reverse transcriptase 
inhibitor (RTI) tenofovir formulated at 1 wt% in a vaginal gel (the prodrug form of 
tenofovir is already taken orally as part of highly active antiretroviral therapy for HIV-
infected individuals).  Although adherence to the gel dosage regimen was still low (less 
than 75% on average), the product demonstrated 39% overall effectiveness to become the 
first clinically effective microbicide and validating RTIs for microbicide applications (1). 
However, the follow-on VOICE trial tested the same tenofovir gel formulation and found 
no effectiveness, albeit with a different dosing regimen (87). Altogether, two major 
conclusions have been made from the microbicide trials performed to-date: First, 
5 
 
targeting specific steps in the HIV replication cycle with highly active and target-specific 
compounds will improve effectiveness over nonspecific and low activity compounds due 
to improved safety and specificity. Second, delivering these compounds from dosage 
forms that provide controlled, sustained inhibitory vaginal concentrations and potentially 
increased user adherence will improve effectiveness over vaginal gels which have 
demonstrated short duration drug pharmacokinetics and poor user adherence (32, 87).  
 
 
1.3 Intravaginal Rings as Microbicides 
 
Due to the relative infancy of the microbicide field, microbicide formulations 
have typically leveraged many of the older vaginal drug delivery platforms developed for 
contraception, HRT, and vaginal infections. To date, intravaginal drug delivery vehicles 
primarily comprise gels and rings although newer and/or less utilized dosage forms 
include capsules, creams, foams, films, pessaries, sponges, suppositories, diaphragms, 
tablets, and tampons (100). Excluding intravaginal rings (IVRs), all of the above dosage 
forms may need to be frequently applied due to their relatively short therapeutically 
effective duration (hours to days), often require dosing before or after sex (coitally 
dependent), and typically provide dynamic vaginal pharmacokinetics. In contrast, IVRs 
are capable of weeks to months duration and can provide controlled drug release kinetics 
to more consistently maintain desired vaginal drug concentrations. Furthermore, IVRs 
possess favorable user attributes such as the potential for discreet use without interference 
or detection during sex, allowance for sexual spontaneity due to their long duration, and 
avoidance of product messiness or leakiness. Although not proven, microbicide IVRs are 
expected to improve both vaginal pharmacokinetics and user adherence over the 
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commonly used gel dosage form and are increasingly desired by the HIV prevention field 
in the search for a highly effective HIV prophylactic product (29, 86, 87).   
Torus shaped IVRs are prepared from “rubbery” polymers that deform elastically 
when pinched into an oval or figure-eight shape. The use of intravaginal elastomeric ring-
shaped devices to deliver active pharmaceutical ingredients (APIs) is now over four 
decades old (24, 38, 47, 51, 101). It is not widely known that the contraceptive IVR was 
one of the first controlled release devices studied in the 1970s at the dawn of modern 
drug delivery technology (6). These revolutionary drug delivery devices were the first to 
take advantage of the new mechanistic understanding of controlled drug release from 
solid implants (9-12, 72). When the IVR is placed in the vaginal lumen, the drug 
concentration initially is homogeneous throughout the IVR, but immediately upon 
contact with vaginal tissue a spatial concentration gradient ensues. The drug present on 
the ring surface (at the polymer/tissue interface) is the first to diffuse from the IVR into 
the contacting tissue, transiting through a thin conducting layer of vaginal fluid or 
directly into tissue (Figure 1.1). The rate of drug release is interdependent on a number of 
factors including the solubility of the drug in the elastomer, the diffusion coefficient of 
the drug in the elastomer, the solubility of the drug in vaginal fluid, the volume of the 
vaginal fluid, the partition coefficient of the drug between the IVR and the vaginal fluid 
and tissue, the rate of diffusion and elimination of the drug through the vaginal tissue, 
and the rate of anterior to posterior advection of the vaginal fluid.  To date, the 





1.4 IVR Manufacturing 
 
Four of the five commercial IVRs available to women are based on the silicone 
technology with indications for contraception (Progering® and Fertiring®) and HRT 
(Femring® and Estring®) (6, 20). Silicone IVR manufacturing is strictly limited to 
reaction injection molding wherein silicone elastomer base, cross-linking catalyst, and 
drug are mixed and subsequently injected under high pressure into a mold where the 
silicone addition-cure or condensation-cure reaction occurs under elevated temperature 
(48). The most recent commercially available IVR, marketed in 2002, is the dual 
hormone contraceptive IVR NuvaRing® (88-91), which was one of the first marketed 
thermoplastic hot melt extruded combination drug-device products. Polymers employed 
for microbicide IVR applications similarly include thermoset silicones (46, 49, 100), 
thermoplastic ethylene-co-vinyl acetate (EVA) (43), and more recently a variety of 
thermoplastic polyurethanes (14, 33, 39). Hot melt extrusion (HME) (30) along with 
injection molding (103) are two common thermoplastic processing methods that can be 
used to fabricate IVRs. HME is a continuous process whereby a screw or screws forces a 
molten material through an opening in an enclosed barrel under elevated temperature and 
pressure. Depending on the application, twin-screw extruders may be used to facilitate 
mixing of additives (i.e., excipients or API) or a single screw extruder may be used to 
provide more precise pressure and tighter control of shaped-product dimensions. 
Although HME has been used for decades in the plastics and medical device industries, 
its potential has only recently begun to be realized in the pharmaceutical industry (23). 
Over the last decade the number of patents, publications, and marketed pharmaceutical 
products has exponentially increased (67). There are several advantages of HME for 
8 
 
pharmaceutical and combination drug-device products including simultaneous 
API/carrier compounding and shaping, increased API bioavailability due to formation of 
a solid state solution (molecularly dissolved API), solvent-free processing to negate use 
of volatile and/or toxic solvents, and potentially reduced manufacturing costs since it is a 
continuous process in contrast to conventional pharmaceutical batch-processing (18). 
Furthermore, due in part to its extensive development in the plastics and medical device 
industries, HME is a highly controlled and monitored process that enables quality by 
design and process analytical technology - concepts strongly favored by the Food and 
Drug Administration (67).  
HME is an extremely versatile process and a variety of shaped and multilayered 
products may be made depending on equipment and accessory configuration. For 
example, the reservoir IVR NuvaRing® is made via coaxial extrusion which involves 
simultaneously using two extruders to feed a drug-loaded EVA core and an EVA rate-
controlling membrane into a crosshead, resulting in a continuously extruded layered 
reservoir type product. Two significant drawbacks of HME for pharmaceutical 
applications are API chemical and physical stability; APIs that are thermally labile may 
be poor HME candidates although steps can be taken to minimize the extent of thermal 
degradation. Also, APIs that are formulated in the polymeric carrier above their 
maximum solubility at storage temperature can achieve API supersaturation during the 
elevated processing temperatures, resulting in a thermodynamically physically unstable 
system where API may bulk- or surface-crystallize during storage (7, 14, 90). Therefore, 
chemical and physical API stability must be considered in the potential development of a 
HME drug product.  
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1.5 IVR Design and Classification 
 
 IVRs are generally categorized as either matrix or reservoir type and offer 
different advantages. A matrix IVR contains drug which is homogenously dissolved or 
dispersed throughout the entirety of the elastomeric polymer, whereas a reservoir IVR 
typically utilizes a drug loaded polymeric core surrounded by a thin layer of polymer of 
the same or different composition (termed a rate-controlling membrane) to impede and 
thus regulate drug diffusion (66) (Figure 1.2). Matrix IVRs, owing to their simpler design 
and construction, are often cheaper to fabricate yet typically provide time-dependent 
release kinetics proportional to the square root of time with less flexibility in modulating 
the release kinetics (46). Conversely, reservoir IVRs are generally more costly to 
fabricate but offer near time-independent drug release kinetics and easier modulation of 
the release rate (91). The literature provides general equations describing drug release 
from matrix- and reservoir-type drug delivery devices (Equation 1.1 and 1.2, 
respectively) based on the Higuchi equation (26):  
 
 







where Q is the cumulative amount of drug released per unit surface area, A is the drug 
loading per unit volume, C is the solubility of drug in the polymer per unit volume, D is 
the diffusion coefficient in the polymer, t is time, and h is the rate controlling membrane 





in the outer polymer).  An additional consideration beyond the desired drug release 
profile is the drug release rate; reservoir IVRs of a given polymer will typically 
demonstrate decreased release rates at early time compared to matrix IVRs due to the 
rate-controlling membrane which impedes drug diffusion (56). Therefore, selection of a 
matrix-type or reservoir-type IVR design will depend on the clinical needs and which 
drug release specifications are most critical to achieve. For example, delivery of 
contraceptive hormones requires low but consistent daily release rates (i.e., micrograms 
per day) due to their relatively narrow therapeutic window and high activity; therefore 
reservoir IVRs are more suitable than matrix IVRs in this instance. An interesting 
exception to IVR classification exists when matrix IVRs demonstrate time-independent 
drug release. In the case termed partition controlled release, the drug demonstrates 
elevated solubility in the polymer and significantly lower solubility in the vaginal fluid  
and furthermore is formulated at high weight percent in the polymer with a fairly large 
polymer diffusion coefficient (9). If these conditions are satisfied, time-independent 
release has been observed since dissolution into the vaginal fluid is the rate limiting step, 
in contrast to the more typical matrix controlled release discussed above where diffusion 
through the polymer to the IVR surface is the rate limiting step (69).   
Although the primary function of an IVR is to deliver therapeutics to the vaginal 
tract, IVRs must also possess certain dimensions and mechanical properties in order to be 
inserted and retained in the vaginal tract - both from an ease-of-use and device 
functionality perspective. Vaginal rings should exhibit an elastic nature since the IVR 
must be compressed to be inserted, yet have sufficient recoil force once in place so as to 
be retained in the vaginal tract. A force balance thus exists between the elastic recoil of 
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the IVR and the musculature of the vaginal wall, with ring dimensions and material 
elastic modulus determining the final conformation and retention of the IVR. Marketed 
vaginal ring outer diameters and cross-sectional diameters range from 54 to 58 and 4 to 9 
mm, respectively (2). The four marketed silicone rings (Estring®, Femring®, Progering®, 
and Fertiring®) possess a significantly lower elastic modulus than the marketed EVA ring 
(NuvaRing®). As a result, the silicone rings encompass the larger dimensions to increase 
ring rigidity whereas the EVA ring is the smallest with a 54 by 4 mm outer diameter and 
cross-sectional diameter, respectively.  To arrive at these finalized ring dimensions 
during product development, several clinical studies evaluated silicone or EVA rings of 
various cross-sectional diameters and elastic moduli in women who used them for 
extended durations up to a year, and user acceptability, functionality, and/or effects to the 
vaginal epithelium were monitored. It was discovered that rings with relatively lower 
cross-sectional diameters (resulting in a mechanically softer ring) had a higher rate of 
vaginal expulsion or ring movement due to their lower elastic recoil force (41, 70). 
However, if the ring elastic recoil force was too great, there was some evidence that users 
had greater difficulty inserting the ring and that the ring may have caused trauma to the 
vaginal epithelium (96). Logically there exists an optimum range of IVR stiffness  
keeping in mind that there will be a wide range of vaginal shapes and sizes among the 
female user population (60-62). In one particularly large clinical study, four rings of 
wide-ranging stiffness were evaluated and all were observed to provide no vaginal trauma 
compared to the naïve arm (27). Since there is no quantitative model to determine the 
ideal mechanical properties of a vaginal ring, early microbicide IVR development may 
benefit by demonstrating similar ring stiffness to the above mentioned marketed products 
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which have exhibited high user acceptability and safety in large user populations. Also, a 
mechanical model relating the force required for the point compression of thin elastic 
rings may be useful for IVR research to better understand the influence of variables such 









where F is force, E is the elastic modulus, ro is the cross-sectional outer radius, R is the 
ring outer radius, and Y is the reduction in ring outer diameter. The fourth-power force 
dependence yet third-power volume dependence on the cross-sectional ring diameter 
(assuming a fixed ring outer diameter) allows for flexibility when designing an IVR. 
Also, IVR compression force is linearly related to the elastic modulus of the IVR matrix, 
which can be affected by the class or grade of polymer used and by incorporation of 
drugs or excipients. Although this mechanical model ignores polymer viscoelasticity and 
assumes linear stress-strain behavior, which is invalid for high ring deformations such as 
during ring insertion where polymer, the model can still be a useful tool for ring design, 
especially when considering small ring deformations such as those seen in a magnetic 
resonance imaging assessment of NuvaRing® retention in the female vaginal tract (5).  
 
 
1.6 Acceptability and Adherence 
 
In the context of microbicides, the terms "acceptability" and "adherence" are often 
misused interchangeably and therefore should be defined and distinguished. Acceptability 




adherence refers to the extent to which users obey specified dosing instructions. Although 
acceptability and adherence will often correlate, the specific relationship between the two 
has not been well defined in the context of microbicides. Clearly, however, an efficacious 
microbicide product must be desirable to women (i.e., possess high acceptability) or the 
product will not be used (i.e., demonstrate low adherence) and its real world effectiveness 
will be limited (52).  Few microbicide IVR acceptability studies have been performed but 
it is hypothesized that microbicide IVR acceptability will be similar to contraceptive 
IVRs, which have been extensively evaluated. In a multinational clinical trial, 66% of the 
women initially preferred oral contraceptives but after NuvaRing® use 81% preferred the 
vaginal ring (57). The change in contraceptive preference was mainly attributed to ease of 
use and not having to remember to take a pill each day, and overall acceptability of the 
IVR was approximately 96% (71). However, an important consideration is that IVR 
acceptability in developed countries - where NuvaRing® has been well studied - may be 
different than in developing countries where most microbicide IVRs will be used and 
where women’s perceptions and cultural practices will be diverse. A study in Brazil 
concluded that women found IVRs to be more acceptable than other microbicide dosage 
forms such as gels (35), with long duration and spontaneity being offered as the primary 
reason. Another relevant study for the microbicide field examined African women sex 
workers’ acceptability of IVRs for HIV prevention (76). Most women favored an IVR 
over a gel due to its long duration and covert use - although women were concerned that 
men might detect the ring. Women’s opinions are likely coupled to men’s opinion in the 
many patriarchal societies in the developing world; therefore, men’s concerns and 
opinions on IVRs should not be discounted. In the study, men’s primary concerns were 
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feeling the ring during intercourse, yet overall thought it more acceptable than a gel that 
may give undesired vaginal lubrication. Since both sexes were concerned about the 
possibility of male contact with the ring during coitus, the study suggests that IVR 
dimensions should be minimized to decrease the probability of this event. Most recently, 
an extensive acceptability study was performed where 157 young African women 
inserted a placebo silicone ring for 12 weeks (86). In general, women found the IVR 
favorable and were attracted by its potential for discreetness, noninterference with coitus, 
and continuous use capability which could allow for spontaneity or protection against 
HIV in the case of rape. 67% of female participants considered it important for their male 
partner to not detect the ring during intercourse, and 63% and 13% feared that their 
partner may become angry or physically abusive, respectively, if the ring was discovered.  
It is worth noting that both African acceptability studies evaluated silicone IVRs with 
roughly twice the diameter of the contraceptive NuvaRing®. Although the majority of 
men did not feel the ring during intercourse, minimizing IVR dimensions will likely 
increase women’s confidence in the discreet capability of the IVR and decrease the 
probability of undesired male contact with the ring during coitus.   
 An excellent review article by Heise et al. discusses microbicide prevention trials 
and considerations when interpreting success of user-controlled methods (36). The 
authors define efficacy as an improvement in outcome under ideal conditions (perfect 
use) whereas effectiveness is the improvement in outcome achieved in practice 
(imperfect or inconsistent use). The microbicide field is concerned with adherence in 
clinical trials, especially following the Carraguard vaginal gel clinical trial where women 
adhered to the dosing regimen only 42% of the time (75). This result brought the 
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realization that product efficacy is meaningless for prospective microbicide products 
demonstrating low user adherence, as the overall effectiveness is so low. In the 
CAPRISA 004 trial with the TFV 1% gel, user adherence positively correlated with HIV 
prophylaxis. The hope is that a long-lasting, coitally-independent IVR will increase 
adherence and therefore effectiveness, shortening the gap between efficacy and 
effectiveness. We warn that there are little data supporting this hope. In fact, the 21 day 
NuvaRing® is only as good at preventing unplanned pregnancy as the once daily oral 
contraceptive (6), and only a 9-12% increase in adherence is achieved for various 
pharmaceutical products when going from daily to weekly frequency with an overall 
trend of intermittent dosing having higher adherence than frequent dosing (42, 58). 
However, the messy, nondiscreet, and burdensome gel dosage form may not be a fair 
comparison to the oral dosage form which generally demonstrates good user adherence. 
Little data exists on nonuser reported once per month administration, but methods to 
accurately measure microbicide adherence are being developed (79, 81). 
 
 
1.7 Microbicide IVR Limitations and Unknowns 
 
As discussed previously, an advantage of the EVA polymer technology over the 
silicone polymer technology is the ability for continuous and controlled manufacturing. 
Equally important, however, is the ability to more easily modulate ring stiffness (since 
silicone possesses a relatively narrow elastic modulus range) so that IVR cross-sectional 
diameter can be reduced to potentially increase user acceptability. Although NuvaRing® 
development has advanced IVR technology, both silicone and EVA IVR platforms have 
only demonstrated success to deliver hydrophobic small molecules at micrograms/day 
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levels. Numerous microbicide IVRs have been developed using these platforms to deliver 
hydrophobic small molecule antiretrovirals and one product is advancing for clinical 
efficacy evaluation (55). Clearly, however, the vaginal drug delivery field would benefit 
from IVR platforms which 1) can provide controlled and sustained delivery of doses 
higher than micrograms/day and 2) can deliver APIs besides hydrophobic small 
molecules. Unfortunately, many hydrophilic APIs are minimally soluble in the silicone 
and EVA polymers and therefore often cannot be delivered by simple diffusion at desired 
release rates for sustained duration. The hydrophilic small molecule tenofovir is a key 
example of current IVR technology inadequacy; Tenofovir was recently proven effective 
against HIV when formulated in a vaginal gel yet lacks a suitable IVR delivery system 
due to insufficient release rates from conventional EVA and silicone polymers (77). In 
addition to hydrophilic small molecules, there are a diverse set of macromolecular and 
biopharmaceutical APIs (including nucleic acids, peptides, and proteins) (97-99) that may 
be potential topical microbicides. However, biologics will require unconventional IVR 
designs as they often cannot withstand conventional IVR processing temperatures 
required for injection molding and hot melt extrusion, and/or have limited diffusivity in 
elastomeric polymers due to their size and limited polymer solubility (98). Therefore, 
designing IVRs for long-term delivery of drugs with wide ranging physicochemical 
properties and desired release kinetics is challenging and will require new and innovative 
technology.  
 The primary objective of microbicide IVRs is to deliver antiretrovirals locally to 
prevent initial infection of susceptible immune cells in the vaginal tract, and therefore 
knowledge of spatiotemporal vaginal drug concentrations is deemed crucial to device 
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success. Since all of the currently marketed IVRs target systemic hormonal delivery, 
there is very limited knowledge about the vaginal biodistribution and pharmacokinetics 
of drugs that are delivered from IVRs. Prior to initiation of the dissertation work reported 
herein, there were no peer-reviewed in vivo studies in women or large animals to examine 
safety, vaginal biodistribution and pharmacokinetics, or potential efficacy of microbicide 
IVR formulations. To evaluate some of these critical unknowns prior to testing in 
women, several animal models offering unique advantages and disadvantages are now 
being utilized by the field (92, 94). A comparison of vaginal mucosal models is presented 
in literature (17, 78). The cheapest yet least relevant animal models for HIV prophylaxis 
are rodents and rabbits. Their vaginal anatomy and physiology are quite different from 
women, but clearly are a step forward from in vitro studies and may offer a quick, low 
cost option for screening potential formulations prior to testing in more relevant animal 
models. The rabbit vaginal irritation model is widely used for preliminary microbicide 
safety studies as it is currently a required preclinical test by the Food and Drug 
Administration (21, 22), and more recently pilot pharmacokinetic studies have been 
performed with rabbits (13, 15).  A major drawback of testing microbicide IVRs in 
rabbits has been the need to suture devices in place to avoid expulsion from the vaginal 
tract. The invasive suturing procedure causes tissue trauma at the implant site and may 
likely impact safety and pharmacokinetic outcomes. To improve the relevancy and 
usefulness of this model, a shape memory polyurethane fixture was recently invented in 
our laboratory which allows for nonsurgical device insertion and retention of the test 
article in the vagina.  
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Amongst large animal models, the sheep model has only recently gained traction 
and greater use for microbicide safety and pharmacokinetic evaluation. The sheep vaginal 
anatomy and stratified squamous epithelium are similar to humans and thus offer two 
significant improvements over small animal models. Due to their anatomical similarity to 
women, human-sized IVRs may be tested in sheep although significant deviations include 
different native vaginal microflora and a vaginal fluid pH of approximately 8 as opposed 
to 4.5 in women (78, 95). The pig animal model, particularly the minipig species, has 
remarkably similar anatomy and physiology to women and also shows promise for 
microbicide safety and pharmacokinetic testing (85). Pigs display a similar acidic pH to 
women although their microflora is generally dissimilar (19, 44, 54). Depending on the 
species utilized, a human-sized IVR could potentially be tested in pigs. 
Although the preceding animal models each have unique advantages and may be 
appropriate for certain stages and objectives during microbicide IVR development, 
nonhuman primates are considered the most relevant animals for HIV prophylaxis 
research since they exhibit the most similar anatomy and physiology to humans (80, 94). 
One particular advantage of pigtail and rhesus macaques for microbicide testing is that 
their vaginal microflora is most similar to women, with the presence of lactic acid 
secreting lactobacillus which maintains an acidic vaginal pH to provide an innate defense 
against pathogens (59, 102). As a result, the potential negative effects of microbicide 
formulations on endogenous microflora, in addition to the vaginal epithelium, can be 
evaluated in the pigtail and rhesus models. Another potential advantage of the pigtail and 
rhesus models is the capability to perform efficacy studies of microbicide formulations 
using the related simian immunodeficiency and simian-human immunodeficiency 
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viruses, although the ability of these viral challenge studies to accurately predict HIV 
infection and prophylaxis in women is uncertain and the subject of debate (80).  
In deciding between rhesus and pigtail macaque models for IVR evaluation, 
several aspects must be considered. Readers are pointed towards comprehensive reviews 
of microbicide animal models, which includes rhesus and pigtail macaques (93, 94), but 
two major differences are highlighted: First, pigtail macaques cycle monthly (akin to 
women) whereas rhesus are seasonal breeders (64). Therefore, rhesus macaques may 
require progesterone administration to synchronize their menstrual cycle. Unfortunately, 
this treatment thins the vaginal epithelium and thereby increases API as well as virus 
permeability (45, 93). Secondly, the supply of pigtail macaques is quite limited and 
therefore large studies and/or cost may necessitate the use of rhesus macaques. 
Altogether, both species still cost significantly more to purchase and house compared to 
the other animal models discussed, thereby potentially limiting experimental design and 
statistical analyses.  
Another drawback of the macaque model is scaling issues related to their smaller 
vaginal anatomy compared to women, complicating the correlation of pharmacokinetics 
between macaques and women and preventing the testing of human-sized vaginal rings. 
The Centers for Disease Control and Prevention recently evaluated various size rings in 
both rhesus and pigtail macaques and found that 25 mm outer diameter IVRs fit well with 
no mucosal inflammation or lesions (64). If ring outer diameter is reduced from the 
human-sized 55 mm to 25 mm yet the same cross-sectional diameter is maintained, ring 
mass and surface area is reduced by approximately 60%. Since the drug release rate is 
proportional to the change in ring surface area (26), the reduction in ring size also 
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corresponds to a 60% decrease in release rate. The average woman weighs approximately 
10 times that of a macaque (59, 74), therefore simply scaling drug release by body mass 
(weight/weight) results in an approximately 6-fold higher overall exposure of drug in the 
macaque than in women.  Similarly, an approximation of vaginal volume, given mean 
length and diameter measurements (4, 59), also results in a 6-fold difference between 
macaques and women. Therefore, these issues should be considered when designing 
macaque studies and performing pharmacokinetic extrapolations from macaques to 
women. 
 Animal models for microbicide IVR evaluation are only now being developed. To 
date, there are many unknowns related to microbicide IVR in vivo performance, 
particularly vaginal biodistribution and pharmacokinetics, formulation effects on the 
vaginal epithelium and endogenous microflora, and the required vaginal concentrations 
for potential effectiveness against HIV. Many unanswered questions exist, such as how 
long after ring insertion does it take for vaginal fluid and tissue drug concentrations to 
reach protective levels? Specifically, what are the spatiotemporal drug concentrations 
proximal to the ring at the endocervix as well as near the introitus which is centimeters 
away from ring placement? How long after IVR removal are protective concentrations 
maintained? Drug release kinetics from IVRs have primarily been tested in vitro using 
sink conditions wherein the concentration of the drug in the release media is never 
allowed to exceed one-tenth its maximum solubility. Whether these in vitro conditions 
are predictive of in vivo performance is unclear, especially for hydrophobic antiretrovirals 
which display poor aqueous solubility and may thus achieve saturated concentrations in 
the vaginal fluid. The selection of an appropriate animal model should depend on the 
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main study objectives and questions asked, and several factors should be considered 
including cost and study size, anatomy and physiology, ring size and scaling, and whether 





In summary, this work is motivated by an overall desire to develop prophylactic 
methods and products to prevent HIV transmission. Specifically, the focus of this 
dissertation work is to develop long-lasting intravaginal ring technologies which can 
deliver proven antiretrovirals to the vaginal tract to prevent the male-to-female sexual 
transmission of HIV. Intravaginal rings offer several advantages over other candidate 
vaginal dosage forms to locally deliver antiretrovirals; First, their extended duration 
capability can minimize final product cost through amortization. Second, their long-
lasting, non-messy, coitally independent, and discreet potential may help increase user 
adherence. Finally, their inherent ability to provide long-duration, controlled drug release 
may enable IVRs to better attain and maintain effective prophylactic vaginal 
concentrations in contrast to less controlled and short-duration dosage forms.  
 Although intravaginal rings hold promise for microbicide applications, there has 
been little design innovation since their initial development decades ago for contraceptive 
and hormone replacement indications. As a result, IVR delivery of therapeutics which are 
not highly active hydrophobic small molecules is generally suboptimal. Furthermore, as 
intravaginal ring technologies have historically aimed for systemic delivery of 
therapeutics, there is little understanding of drug vaginal biodistribution and 
pharmacokinetics from IVRs, or of IVR effects on the vaginal environment pertaining to 
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safety. Thus, the primary focus of this dissertation work is to 1) design new intravaginal 
rings capable of delivering a variety of antiretrovirals and 2) develop new in vitro tests 
and in vivo models to increase IVR performance understanding and thereby provide new 
IVR platforms and products to prevent the sexual transmission of HIV.  
 
 
1.9 Dissertation Chapter Overview 
 
Each following chapter is a separately published manuscript or is pending 




1.9.1 Chapter 2 overview 
In Chapter 2, we sought to design and test in vivo a polyurethane intravaginal ring 
to deliver the promising small molecule antiretroviral agent congeners IQP-0528 and 
IQP-0532. In particular, this dose-finding and safety study aimed to determine 1) whether 
loading-dependent drug release is observed in vivo as is observed in vitro, 2) what IVR 
drug loading would achieve vaginal concentrations deemed to be sufficient to prevent 
HIV infection, and 3) whether the formulations cause any harm or irritation to the vaginal 
mucosa and endogenous microflora. The two congeners were evaluated at various 
loadings in pigtail macaques and compared to placebo and naïve control arms.  The 
primary study output was vaginal pharmacokinetics and safety. This was the first peer-
reviewed publication reporting drug safety and pharmacokinetics of a microbicide IVR in 
nonhuman primates.  
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Publication: Johnson T. J., Srinivasan P., Albright T. H., Watson-Buckheit K., Rabe L., 
Martin A., Pau C.P., Hendry R.M., Otten R., McNicholl J., Buckheit R., Smith J., Kiser 
P.F. Safe and Sustained Vaginal Delivery of Pyrimidinedione HIV-1 Inhibitors from 




1.9.2 Chapter 3 overview 
In Chapter 3, we sought to develop a combination IVR to simultaneously deliver 
the two promising antiretroviral molecules dapivirine and tenofovir which possess 
different mechanisms of HIV inhibition and contrasting hydrophilicity. Combination 
microbicides are under development to reduce the probability of drug-resistant virus 
which could arise from single agent HIV prophylaxis. The delivery of tenofovir from 
conventional hydrophobic polymer IVRs has proven inadequate owing to its 
hydrophilicity and low polymer miscibility. Our main aims were to 1) design and 
characterize a new IVR platform to improve tenofovir release rates over conventional 
IVRs, and 2) provide sustained release of both dapivirine and tenofovir for up to 30 days. 
This was the first peer-reviewed publication of an advanced multi-segment IVR platform 
to deliver multiple antiretrovirals, and the first report of using hydrophilic polyurethanes 
for IVR applications.  
Publication: Johnson T.J., Gupta K.M., Fabian J., Albright T.H., Kiser P.F. Segmented 
Polyurethane Intravaginal Rings for the Sustained Combined Delivery of Antiretroviral 
Agents Dapivirine and Tenofovir. European Journal of Pharmaceutical Sciences, 2010. 
39: p. 203-212. 
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1.9.3 Chapter 4 overview 
In Chapter 4, we sought to design and evaluate in a sheep animal model a 
tenofovir (TFV) reservoir IVR which could avoid the time-dependent TFV release 
kinetics and ring mechanical stiffness observed with the matrix IVR developed in 
Chapter 3.  Our main aims were to develop a ring that could 1) attain similar vaginal TFV 
concentrations as the clinically effective TFV 1% gel but for 90 day duration, 2) show no 
harmful vaginal effects, and 3) achieve time-independent ring mechanical stiffness 
similar to commercially available IVRs. This was the first publication to demonstrate 
similar or higher TFV vaginal concentrations from an IVR compared to the TFV 1% gel, 
and furthermore in a time-independent fashion for 90 days with no significant 
toxicological effects.  
Publication: Johnson T.J., Clark M.R., Albright T.H., Nebeker J.S., Tuitupou A.L., Clark 
J.T., Fabian J., McCabe R.T., Chandra, N., Doncel, G.F., Friend D.R., Kiser P.F. A 
Ninety Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis. 
Antimicrobial Agents and Chemotherapy. Under Review. 
 
 
1.9.4. Chapter 5 overview 
In Chapter 5, we sought to further design and characterize the TFV IVR prototype 
reported in Chapter 4. Our main aims were to 1) design and test IVRs of various 
composition and dimension to arrive at an optimized design and better understand the 
design space, and 2) determine the underlying mechanism behind drug release rate 
changes as a function of product storage time in order to achieve a thermodynamically 
stable formulation. This manuscript reported the engineering of an unconventional 
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reservoir IVR platform which could be used to deliver a spectrum of therapeutics and is 
the first publication to demonstrate and explain the impact of polyurethane microphase 
separation kinetics on drug flux. This was also the first IVR platform capable of 
delivering daily milligram quantifies of an API for greater than 30 days, and moreover 
while maintaining time-independent ring mechanical stiffness. 
Publication: Johnson T.J., Nebeker J.S., Tuitupou A.L., Smith E.M., Clark J.T., Fabian J., 
McCabe R.T., Clark M.R., Friend D.R., Kiser P.F. Engineering of a New Intravaginal 




1.9.5. Chapter 6 overview 
 In Chapter 6, brief conclusions of the dissertation work will be drawn and 
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Figure 1.1. Diagram of in vivo drug release and transport from an IVR. A. Diffusive 
transport of drug from an intravaginal ring directly into vaginal tissue or first into a thin 
conducting layer of vaginal fluid and then into vaginal tissue, with transport into the 
blood being the ultimate sink. B. Advective transport of the drug in vaginal fluid from the 
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A NINETY DAY TENOFOVIR RESERVOIR INTRAVAGINAL  





A vaginal gel containing the antiretroviral tenofovir (TFV) recently demonstrated 
39% protection against HIV infection in women. We designed and evaluated a novel 
reservoir TFV intravaginal ring (IVR) to potentially improve product effectiveness by 
providing a more controlled and sustained vaginal dose to maintain cervicovaginal 
concentrations. Polyurethane tubing of varying hydrophilicity was filled with a high 
density 65/33/2 weight percent TFV/glycerin/water semisolid paste and then end-sealed 
to create IVRs. In vitro, TFV release increased with polyurethane hydrophilicity, with 35 
weight percent water swelling polyurethane IVRs achieving approximately 10 mg/day 
release for 90 days with similar mechanical stiffness to commercially available 
NuvaRing®. This design was evaluated in two 90 day in vivo sheep studies for TFV 
pharmacokinetics and safety. Overall, TFV vaginal tissue, vaginal fluid, and plasma 
levels were relatively time-independent over the 90 day duration at approximately 104 
ng/g,  106 ng/g, and 101 ng/mL, respectively, near or exceeding peak concentrations in a 
TFV 1% gel control group. TFV vaginal fluid concentrations were approximately 1000-
fold greater than levels shown to provide significant protection in women with the TFV 
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1% gel. There were no toxicological findings following placebo or TFV IVR treatment 
for 28 or 90 days, although modest increases in inflammatory infiltrates in the vaginal 
epithelia were considered to be TFV- and/or ring-related and warrant additional safety 
and efficacy assessment. In summary, this reservoir IVR provided controlled yet 
significant daily release of TFV to maintain elevated sheep vaginal concentrations for 90 





Recent progress in antiretroviral HIV prevention research has advanced the field 
from concept toward medical practice (46). The CAPRISA 004 study demonstrated that a 
vaginal gel containing the reverse transcriptase inhibitor tenofovir (TFV) was partially 
effective in preventing HIV transmission in women (1), with significant protection 
observed in women who maintained preventative TFV concentrations of at least 1000 
ng/mL in vaginal fluid (23).  However, the overall effectiveness (39%) likely was 
reduced by poor user adherence to the inconvenient "before-and-after-sex" dosing 
regimen. The correlation of adherence and TFV vaginal fluid concentrations to protection 
was a key finding (23, 24, 45), indicating the need for vaginal drug delivery systems that 
attain and maintain elevated user adherence and vaginal drug concentrations. More 
recently, the VOICE trial tested the same TFV 1% gel formulation as CAPRISA 004 but 
with a once daily dosage regimen, and failed to show any effectiveness in women. Here 
as well, low adherence may have contributed to the gel’s inability to prevent HIV 
transmission (54). As a result, we (6, 21) and others (4, 35, 36, 44, 49) aim to develop 
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TFV drug delivery systems to provide sustained protective vaginal tissue concentrations 
and potentially increase user adherence. 
The micromolar anti-HIV activity of TFV motivated selection of the high dose in 
the CAPRISA 004 trial (up to two 40 mg doses within 24 hours). Inter- and intra-user 
TFV vaginal fluid and tissue concentrations were likely dependent on several poorly 
understood factors and processes, such as adherence, time between gel applications, 
vaginal product clearance, menstrual cycle phase, vaginal fluid volume and composition, 
and frequency of intercourse (i.e., more sex acts over a given time would result in higher 
vaginal TFV administration since the dosing regimen was coitally dependent).  
Moreover, episodic dosage forms like gels are intrinsically short acting; the TFV 1% gel 
formulation attains peak vaginal tissue concentrations in women two hours post-vaginal 
application and diminishes rapidly thereafter (45). Finally, the anatomical site and 
kinetics of HIV transmission itself are poorly understood (19). Therefore, a drug delivery 
system that maintains elevated yet controlled and consistent TFV cervicovaginal tract 
drug concentrations over a duration longer than HIV transmission and throughout 
multiple episodic HIV exposures has the potential to increase efficacy over the dynamic 
drug levels provided by vaginal gels.  
The silicone intravaginal ring (IVR), invented in 1970 (8, 34), was designed to 
elute hormones for a 30 day duration and provide sustained drug levels in the range of 10 
to 100 μg/day. Since then there has been little innovation in IVR technology. In fact, 
current IVR technology is inadequate to meet the high topical dose requirements of TFV. 
Groups have claimed successful TFV formulation and delivery from silicone- and 
ethylene vinyl acetate-based IVRs (4, 35, 36, 44, 49), yet the in vitro and in vivo daily 
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delivery rates reported were micrograms, rather than milligrams, as is required for HIV 
prophylaxis with TFV. The TFV release from silicone and ethylene vinyl acetate 
polymers is therapeutically insignificant primarily due to TFV’s hydrophilicity and 
resultant low solubility in these elastomeric polymers commonly used for IVRs.   
Although IVRs have a higher per-unit cost compared to gels, for a global health 
application they offer the advantage of distributing the per-unit cost over many days, 
weeks, or months (15). Therefore, from an economic perspective a long-lasting and low 
manufacturing-cost IVR could be more affordable than a frequently applied gel since 
hundreds of gel units would be needed per year compared to several rings. However, 
developing a long-duration IVR to deliver milligrams-per-day of TFV for at least 90 days 
requires a design capable of delivering approximately 1 gram of TFV from a 3 - 6 gram 
IVR. With such a high weight fraction of drug incorporated in the IVR, maintaining both 
time-independent TFV release and ring mechanical stiffness for a 90 day duration 
presents a significant design challenge. We recently reported TFV delivery from 
hydrophilic polyether urethane (HPU) matrix IVRs formulated with up to 20 weight 
percent (wt%) TFV (6, 21). Although TFV release rates were greatly improved compared 
to hydrophobic polymer IVRs, matrix IVRs inherently demonstrate decreased drug 
release rates with time. Matrix IVRs with a high fraction of undissolved drug similarly 
display time-dependent decreases in mechanical stiffness as the drug is released. 
Therefore, we developed and evaluated in vitro and in vivo the first reservoir IVR using a 
water-absorbable polyurethane as a rate controlling membrane capable of delivering 10 to 
30 mg of TFV daily for up to 90 days.  Herein, we report the ring’s in vitro/in vivo TFV 
release, mechanics, and vaginal safety and TFV pharmacokinetics in a sheep model. 
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4.3 Materials and Methods 
4.3.1 Materials 
Hydrophilic aliphatic polyether urethane (HPU) Tecophilic® HP-60D-20, HP-
60D-35, and HP-60D-60 grades were purchased from Lubrizol Advanced Materials 
(Wickliffe, OH), with equilibrium aqueous mass absorption of approximately 20, 35, and 
60 wt% and shore hardnesses of 43D, 42D, and 41D, respectively. A custom-synthesized 
35 wt% swelling HPU with 78A shore hardness was provided by DSM Biomedical 
(Berkeley, CA). Tenofovir monohydrate was supplied by Gilead Sciences (Foster City, 
CA). TFV 1% gel was supplied by Patheon Pharmaceuticals (Cincinnati, OH). USP grade 
glycerol and water were purchased from Spectrum Chemical (New Brunswick, NJ). 
Starch 1500® USP grade partially pregelatinized maize starch was provided at no cost by 
Colorcon (Harleysville, PA). Unless noted, all solvents and reagents were ACS grade. 
 
 
4.3.2 Ring fabrication 
 HPU resins were dried overnight in a compressed air micro dryer (Dri-Air, East 
Windsor, CT) to less than 0.05 wt% water content as determined using Karl Fisher 
titration (Mettler-Toledo, Columbus, OH). The dried pellets were fed into a 3/4-inch 
single screw hot-melt extruder attached to an advanced torque rheometer drive (C.W. 
Brabender, South Hackensack, NJ) with a tubing crosshead (Guill Tool, West Warwick, 
RI). The extruder heating zones (1 - 3) were set at 150, 160, 170°C and the tubing 
crosshead tip and die temperatures were 150°C and 130°C, respectively. Upon leaving 
the crosshead, the extrudate was drawn down using a CPC2-12 combination puller/cutter 
(Conair, Cranberry Township, PA) to create a final tubing product with 0.7 mm wall 
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thickness and 5.5 mm cross-sectional diameter. The extruded tubes were cut to 171 mm 
in length, weighed, and the tubing lumens were filled with either 100% TFV powder or a 
65/33/2 wt% TFV/glycerol/water mixture, resulting in 1.6 g of TFV loaded into each IVR 
lumen. The TFV/glycerol/water semisolid was mixed using a Hobart mixer with “B” 
beater attachment (Troy, OH) and back-filled into the tubing lumen using a high pressure 
hydraulic filling system (Dymax, Torrington, CT). TFV powder was manually filled into 
the tubing lumen. The tubing ends were sealed using an induction welder equipped with a 
stainless steel reverse bonding die, and the resultant plugged ends were welded together 
using a stainless steel split die induction welder (PlasticWeld Systems, Inc., Newfane, 
NY) to create an IVR. A custom machined 12 cavity aluminum mold was used to shape 
anneal the IVRs in a circular conformation and minimize tubing lumen kinking. IVRs 
were placed in the mold which was first heated via water circulation to 65°C for 15 
minutes followed by 5 minutes cooling at 10°C. 
 
  
4.3.3 In vitro TFV release and IVR mechanical testing 
In vitro release and ring mechanical compression testing were performed as 
previously described (6, 21). Briefly, IVRs were immersed in 50 mL of 25 mM sodium 
acetate buffer (pH 4.2) at 37°C and 80 rpm. Release media was periodically collected for 
TFV concentration measurement by high-performance liquid chromatography (HPLC) 
and replaced every 24 hours to maintain sink conditions. Simultaneously, IVRs were 
periodically subjected to mechanical compression testing. Briefly, a custom machined 
probe attached to an Instron 3342 uniaxial mechanical testing system was used to 
compress the IVR 25% of its initial 55 mm diameter at a rate of 1 mm/sec and record the 
65 
 
result required force. The force value corresponding to 10% ring compression was 
compared across all samples. 
 
 
4.3.4 Drug content analysis for in vitro studies 
TFV in vitro release sample concentrations were determined by HPLC using a 
method previously described (6). Briefly, 2 μL of sample was injected on an Agilent 
1200 series HPLC with diode array detector and Phenomenex Luna C18 5 μm, 150 x 4.6 
mm column. A 15 minute gradient method consisted of 100% mobile phase A (potassium 
phosphate buffer, pH 6.0) switching to 100% mobile phase B (acetonitrile/ potassium 
phosphate buffer, pH 6.0) upon run completion. The flow rate was 1.5 mL/minute with a 
typical TFV retention time of 7 min with TFV detection at 260 nm. Cumulative percent 
release was calculated by numerically integrating between collection time points using 
the trapezoidal rule and subsequently dividing by the original amount of TFV in the IVR. 
 
 
4.3.5 Sheep pharmacokinetic study (study 1) 
The 78A shore hardness HPU IVR (35 wt% swelling) and the clinically tested 
TFV 1% gel were comparatively evaluated for pharmacokinetics in 1 - 2 year old Dorset 
Crossbred sheep. The study was conducted at MPI Research (Mattawan, MI), which is 
fully accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC International). The study protocol was reviewed 
and approved according to the standard procedures of the performing laboratory’s 
Institutional Animal Care and Use Committee. The sheep were housed indoors, and 
fluorescent lighting was provided for approximately 12 hours per day. On occasion, the 
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dark cycle was interrupted due to study-related activities. Reproductive cycles were not 
synchronized, and the study was performed September through December. Eight animals 
in treatment Group 1 received a TFV IVR that was inserted in the posterior vagina on day 
0 and retained in the vaginal tract for 90 days. The exterior of the vagina was cleaned 
with chlorhexadine solution and the IVR was inserted as aseptically as practical using a 
gloved hand. Following insertion, a speculum was used to confirm correct placement of 
the ring and the animals were examined daily for evidence that the ring was still in place. 
If the vaginal ring was expelled or otherwise needed to be replaced, a new ring was 
inserted and the old ring was recovered for residual drug content analysis (if found). 
Seven animals in treatment Group 2 received once daily vaginal administration of 4 mL 
of the TFV 1% gel for 28 days (40 mg/day). Each gel dose was administered using a pre-
filled, single-dose polypropylene applicator (HTI Plastics, Lincoln, NE) similar to that 
used in the clinical gel administration regimen. Vaginal tissue, vaginal fluid, and blood 
plasma periodically were collected for drug content analysis throughout the dosage 
duration and up to three days following the last gel dose or IVR removal, as depicted in 
Figure 4.1. Blood samples (approximately 1 mL) were collected from all animals via the 
jugular vein, placed in tubes containing K3EDTA anticoagulant, and centrifuged under 
refrigeration to isolate the blood plasma. At all specified time points, two Weck-Cel® 
(distributed by Beaver-Visitec International, Inc., Waltham, MA) swabs and biopsies 
were collected per animal for TFV concentration determination in vaginal fluid and 
tissue, respectively, one proximal to the ring (posterior vagina, 5-7 cm from the introitus) 
and one distal to the ring (2-4 cm from the introitus). Weck-Cel swabs were pre-weighed, 
inserted and allowed to absorb fluid for approximately 1 minute and subsequently were 
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removed and re-weighed to determine fluid mass uptake. A Kevorkian-Younge biopsy 
forceps (Miltex, York, PA) and speculum were used to acquire approximately 50 mg 
vaginal tissue biopsies. Local and general anesthetics and analgesics were given on the 
day of biopsy collection and a chlorhexidine solution was used to clean the exterior 
vagina. Vaginal tissue biopsy location (left or right side) was alternated with timepoint to 
minimize tissue trauma and encourage healing. If bleeding was observed after biopsy 
collection, direct pressure with gauze or gauze with thrombin was applied to encourage 
clotting. Upon completion of the 90 day time point, IVRs were removed and analyzed for 
remaining drug content as described below. At study termination on days 93 (Group 1, 72 
hours post-IVR removal) and 31 (Group 2, 72 hours post-last gel dose), surviving 
animals were euthanized by an intravenous overdose of sodium pentobarbital solution 
followed by exsanguination via severing the femoral or axillary vessels, and vaginal 
tissues were collected for final drug content determination. All samples (blood plasma, 
Weck-Cel swabs, and tissues) were snap frozen and stored at -70°C until bioanalysis was 
performed, as described below.   
 
 
4.3.6 TFV measurement in plasma, vaginal fluid, and vaginal tissue 
TFV was extracted from vaginal tissue, vaginal fluid, and plasma and quantified 
by LC/MS/MS similar to methods described elsewhere (7, 36). Briefly, for TFV plasma 
quantification, 100 μL of standard, quality control sample or study sample was mixed 
with 50 μL of a working internal standard TFV-d6 solution at 50 ng/mL. A 500 μL 
aliquot of 0.5% formic acid in water was added to all plate wells, and the samples were 
transferred to a pre-conditioned Oasis MCX solid-phase extraction plate. The plate was 
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then washed with 800 μL of 0.5% formic acid in water and 800 μL of methanol, followed 
by sample elution with 600 μL of 5:95 ammonium hydroxide:methanol. The eluent was 
evaporated to dryness, and the residue was reconstituted with 200 μL of 0.1% ammonium 
hydroxide in water. The samples were vortexed and an aliquot of each sample was 
injected onto an LC-MS/MS system for analysis. Similarly, TFV was measured in tissue 
by mixing 200 μL of standard, quality control sample or study sample with 50 μL of a 
working internal standard solution containing TFV-d6 at 50 ng/mL. The samples were 
vortexed and centrifuged, and an aliquot of each sample was injected onto an LC-MS/MS 
system for analysis. Lastly, TFV levels in swabs were processed by mixing 50 μL of 
standard, quality control sample or study sample with 50 μL of a working internal 
standard TFV-d6 solution (200 ng/mL) in a tube containing a clean spear or study sample. 
A 950 μL aliquot of 50:50 methanol:water was added to the standards and quality control 
samples, whereas a 1000 μL aliquot of 50:50 methanol:water was added to the study 
samples. The samples were vortexed and centrifuged, and an aliquot of the supernatant 
was injected onto an LC-MS/MS system for analysis. 
 The chromatography varied with sample type: plasma samples were analyzed 
using a Phenomenex Synergi Polar-RP column, 75 mm x 2 mm (4 μm particle size) with 
a gradient flow of 0.1% acetic acid in water, 0.1% acetic acid in acetonitrile, and 0.2% 
ammonium hydroxide in water at a flow rate of 300 to 500 mL/minute. Swabs were 
analyzed using the same column but with an isocratic flow of water/acetonitrile/acetic 
acid/ammonium hydroxide (930:70:5:1) (v/v/v/v) at a flow rate of 200 μL/minute. Tissue 
samples were analyzed using a BioBasic AX column, 50 x 3.0 mm (5 μm particle size) 
with a gradient flow of acetonitrile:10 mM ammonium acetate in water at pH 6 (30:70) 
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and acetonitrile:1 mM ammonium acetate in water pH 10.5 (30:70) at a flow rate of 400 
to 1000 mL/minute.  
 The analyte and internal standards were detected using a Sciex API 5000 triple 
quadrupole LC-MS/MS system equipped with an ESI (TurboIonSpray®) ionization 
source operated in the positive and negative ion mode. Multiple-reaction-monitoring 
mode transitions of the respective ions were used to monitor TFV and TFV-d6 and may 
have been slightly modified to optimize system performance. For TFV, m/z 288 to 176 
was monitored with a retention time of 1.15 – 3.67 min. For TFV-d6, m/z 294 to 182 was 
monitored with a retention time of 1.15 – 3.65 min. The lower limits of quantification 
(LOQ) for TFV in plasma, Weck-Cel, and vaginal tissue were 1.00 ng/mL, 5.00 ng/spear, 
and 20.0 ng/g, respectively.  
 
 
4.3.7 TFV pharmacokinetic analysis 
Individual pharmacokinetic parameters were determined by non-compartmental 
methods using WinNonlin® Phoenix software (Pharsight Corporation, Sunnyvale, CA).  
Area under the curve (AUC) estimates were determined using the linear trapezoidal rule 
with the linear interpolation calculation method. Values below the respective LOQs were 
treated as "0" for the analysis. Nominal sample collection time was used for the analysis.  
Pharmacokinetic parameters were defined as follows: Tmax: Time of maximum observed 
concentration; Cmax: Maximum observed concentration occurring at Tmax; and AUC0-90 






4.3.8 Quantification of IVR residual TFV content 
TFV was extracted out of the recovered IVRs to determine the total amount of 
TFV released. Each IVR was cut into approximately 1 cm segments that were placed 
together in a 50 mL volumetric flask, and 100 mM pH 7.4 phosphate buffer was added to 
dissolve the entirety of the residual TFV. After removing the polymer segments, an 
aliquot of the resulting solution was diluted volumetrically and analyzed for TFV content 
by HPLC as previously described (21). Original semisolid material used for IVR 
manufacture was kept and extracted in the same manner to calculate percent recovery 
based on IVR fill mass.  
 
 
4.3.9 Sheep toxicology study (study 2) 
 The local tolerance and systemic toxicity of the 78A shore hardness HPU TFV 
IVR (35 wt% swelling) was assessed in female Welsh Mule sheep (age: 49 months; 
weight at start of study was 59.5 - 83.5 kg) over a 1 month (28 day) or 3 month (90 day) 
period, in comparison with a placebo IVR or sham control (i.e., underwent restraint and 
sham insertion, but no ring was inserted). The placebo IVR consisted of 60/38/2 wt% 
starch/glycerol/water in the tubing lumen but otherwise the IVR was manufactured using 
identical HPU tubing, processes, and equipment as the TFV IVR. The study was 
conducted at Huntingdon Life Sciences (Huntingdon Life Sciences, United Kingdom), 
which is fully accredited by AAALAC International. The study design, outlined in Table 
4.1, was based on the current International Conference on Harmonisation (ICH) 
Harmonised Tripartite Guidance on Non-Clinical Safety Studies for the Conduct of 
Human Clinical Trials and Marketing Authorization for Pharmaceuticals (20), and the 
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study protocol was reviewed and approved according to the standard procedures of the 
performing laboratory’s Ethical Review Process Committee. Physical examinations were 
conducted on all animals pre-treatment.  The animals were observed at least twice daily 
throughout the study for any clinical abnormalities or signs of reaction to treatment.  
More frequent observations were made on the day of dosing.  Body weights were 
recorded weekly and food consumption was recorded on a daily basis. Hematology, 
blood chemistry, and urinalysis were conducted on all animals pre-treatment and pre-
termination (day 28 or day 90).  Upon termination of the study, all animals were 
sacrificed and gross necropsy was conducted.  Most major body organs were isolated and 
weighed. Tissues were then fixed in 10% neutral buffered formalin, embedded in paraffin 
wax, sectioned at approximately 4 - 5 μm thickness and stained with haematoxylin and 
eosin (H&E) for histological examination by light microscopy.  
In addition to the standard analyses described above, H&E stained slides of the 
posterior vaginal tissue (i.e., proximal to IVR location) were used for vaginal irritation 
scoring in accordance with the rabbit vaginal irritation method of Eckstein et al. (9). 
Approximately 10 areas were analyzed using a Nikon 600 microscope and individual 
scores from 0 - 4 were assigned depending on the extent of congestion, edema, leukocyte 
infiltration and epithelial damage. The individual scores were combined to yield a total 
group score (0 - 16) that in rabbits correlates with human irritation potential.  
Similar to the sheep pharmacokinetic study, TFV IVRs were retrieved from the animals 
prior to termination at 28 and 90 days and analyzed for remaining drug content as 
described above. In addition, blood plasma, vaginal fluid (Weck-Cel swabs), and vaginal 
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tissue was collected from the TFV IVR treated animals prior to termination and analyzed 
for TFV content using methods described above. 
 
 
4.3.10 Statistical analysis 
 Data were analyzed using one-way and two-way ANOVA and unpaired two-




4.4.1 In vitro characterization and optimization 
An elastomeric HPU tubular IVR design was utilized as it maximized the weight 
ratio of drug to total device, could be filled with solid or liquefied drug, and provided 
sufficient time-independent mechanical stiffness and drug release. Previous research 
beyond the scope of this publication determined that HPU IVRs of 5.5 mm outer cross-
sectional diameter, 0.7 mm wall thickness, and 55 mm outer diameter (Figure 4.2) would 
provide ring mechanical properties, lumen volume, and drug release kinetics suitable for 
the proposed TFV IVR (see Chapter 5). The in vitro TFV release rate was evaluated 
using various core compositions and equilibrium percent swelling HPU IVRs. IVRs 
containing only TFV powder in the lumen showed low yet steadily increasing TFV 
release rates with time which did not reach steady-state by 28 days (Figure 4.3A). When 
the highly water miscible and HPU-permeable compound glycerol was added into the 
tubing lumen, the lumen was rapidly hydrated and attained the equilibrium TFV release 
rate after only a 1 day transient state. The TFV release rate increased with polymer 
equilibrium swelling for 20, 35, and 60 wt% swelling Tecophilic HPUs. The 20 wt% 
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swelling IVRs did not achieve the desired 10 mg/day minimum release rate and were 
stopped after 28 days, whereas the 35 and 60 wt% swelling IVRs achieved approximately 
17 and 25 mg/day steady-state release rates, respectively. However, TFV was depleted 
from the 60 wt% swelling IVRs before the target 90 day duration. The TFV percent 
cumulative release profile was linear until greater than 90% of the initial drug load was 
depleted from the IVRs (Figure 4.3B). The softer shore hardness 35 wt% swelling HPU 
IVR released 10 mg/day of TFV for 90 days (Figure 4.4A) and demonstrated mechanical 
stiffness similar to NuvaRing (Figure 4.4B).  Furthermore, the HPU IVR stiffness did not 
change considerably with time when comparing the dry state, hydrated state, and after a 
majority of the TFV was released (i.e., 0, 1, and 90 days). Ten percent ring compression 
values were compared as this is approximately the in vivo compression of NuvaRing, as 
determined by Magnetic Resonance Imaging (3).  
 
 
4.4.2 TFV pharmacokinetics in sheep (study 1) 
The HPU TFV IVRs were evaluated in a sheep model to compare the TFV 
pharmacokinetics to the clinically tested TFV 1% gel. Throughout the 90 day duration 
one animal expelled multiple rings, one animal expelled one ring, and two animals 
required a replacement ring due to a ring manufacturing defect and a procedural error 
during pinch biopsy collection which damaged the ring. However, pharmacokinetic data 
from these sheep did not differ from sheep that retained a single IVR for the full 90 day 
duration and thus no data were excluded. One sheep in the TFV gel group expired on day 
15, with complications from anesthesia being determined as the cause of death (non-
treatment related). The calculated time-averaged in vivo TFV release rate from devices 
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that were retained for 90 days in vivo was 17.0 ± 1.1 mg/day (mean ± standard deviation, 
N = 5) as determined by residual TFV extraction, approximately 70% higher than the 10 
mg/day in vitro release rate.  
TFV vaginal fluid concentrations from the IVR group attained their steady-state 
levels of approximately 106 ng/g by day 1, which were maintained for the remainder of 
the 90 day duration (Figure 4.5A). Mean TFV concentrations from IVR insertion through 
90 days were 3.5-fold higher proximal to the ring than distal. Comparatively, steady-state 
mean TFV vaginal fluid concentrations from the IVR group (approximately 106 ng/g) 
were similar to mean TFV vaginal fluid concentrations at 8 hours post-gel dose (Figure 
4.5B). Mean TFV concentrations from the gel group were 1.4-fold higher proximal than 
distal. Up to 3 days beyond IVR removal (Figure 4.6) and after the last gel dose, vaginal 
fluid concentrations for both groups were approximately 104 ng/g.   
Eight hours post-IVR insertion, TFV vaginal tissue concentrations were 
approximately 102 ng/g (Figure 4.7A). TFV tissue concentrations at day 14 (the next 
biopsy time point) through day 90 were approximately 104 ng/g, with concentrations 
trending slightly higher with time. For the full duration of IVR residence in the vaginal 
tract (0 to 90 days), mean TFV tissue concentrations were similar proximal and distal to 
the ring. Mean TFV tissue concentrations were 104 ng/g 8 hours after the 15th gel dose, 
similar to day 14 TFV concentrations with the IVR group (Figure 4.7B). Eight hours after 
the 15th dose and 24 hours after the 28th gel dose, mean TFV levels decreased to 
approximately 103 and 102 ng/g, respectively. TFV tissue concentrations 3 days after IVR 
removal and 3 days after the last gel administration were significantly lower, with several 
biopsies from both groups below the LOQ. Across all gel group time points, mean TFV 
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tissue concentrations were 3.1-fold higher proximal than distal. TFV-diphosphate 
concentration determination in vaginal tissue was also attempted but was undetectable or 
highly variable in both IVR and gel groups and thus was excluded from further analysis 
(data not shown).  
Mean TFV plasma concentrations at day 7 through day 90 from the IVR group 
were steady at approximately 15 ng/mL, with the exception of day 14 where mean 
concentrations were  28 ng/mL (Figure 4.8A). In contrast, the gel group achieved similar 
TFV concentrations at 2 hours but rapidly decayed thereafter (Figure 4.8B). Also in the 
gel group, mean post-dose TFV plasma concentrations decreased with increased dose 
(mean TFV concentrations from the 1st dose > 15th dose > 28th dose). TFV was 
undetectable in plasma at 24 hours post-IVR removal or gel dose. TFV pharmacokinetic 
parameters for vaginal fluid, vaginal tissue, and plasma (Table 4.2) were consistent with 
the data presented above.  
 
 
4.4.3 Toxicological evaluation 
 A second sheep study was performed to evaluate the systemic toxicity and local 
irritation potential of TFV IVRs compared to placebo IVRs and a sham control. IVRs 
were well tolerated and retained, with only one IVR expulsion noted on the day of 
scheduled removal (day 90).  No treatment-related toxicological findings were observed 
regarding body weight, food consumption, hematology, blood chemistry, urinalysis, 
organ weight, and gross pathology. As determined by histopathology, the degree or 
incidence of leukocytic infiltration in the vagina at 1 and 3 months increased with ring 
presence although no epithelial disruption was observed (TFV or placebo, Figure 4.9). 
76 
 
When quantifying the irritation potential in sheep, slight increases in the mean vaginal 
irritation scores were observed for both placebo and TFV IVRs compared to sham 
controls (Figure 4.10). Specifically, mean vaginal irritation scores for sham, placebo 
IVRs, and TFV IVRs at 1 month were 1.8, 2.4 and 3.2, respectively, and at 3 months 
were 2.2, 3.2 and 3.8, respectively. Differences between the TFV IVR and sham control 
were found to be statistically different at both time points (p=0.03 and 0.01 for 1 and 3 
months, respectively). 
Upon animal necropsy at 28 and 90 days, IVRs were recovered for drug content 
analysis and plasma, vaginal fluid, and vaginal tissue were analyzed for TFV 
concentration. The time-averaged TFV release rate of IVRs retrieved from sheep after 28 
and 90 days of treatment was 14.0 ± 2.8 and 16.9 ± 1.6 mg/day, respectively (mean ± SD, 
N = 5). TFV vaginal tissue, vaginal fluid, and plasma concentrations at 28 and 90 days 




We designed and tested a new reservoir intravaginal ring for long-duration TFV 
vaginal delivery. IVR fabrication incorporated materials and manufacturing methods 
commonly utilized by the pharmaceutical and medical device industries, making the IVR 
a scalable and cost-effective product for resource-poor regions where the HIV pandemic 
is most prevalent (51). The 35 wt% swelling HPU released at least 10 mg/day of TFV in 
vitro for 90 days with time-independent IVR mechanical properties. In sheep receiving 
IVRs, TFV concentrations in plasma, vaginal fluid, and vaginal tissue were near time-
independent for 90 days at levels similar to peak concentrations in the TFV 1% gel group. 
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Lastly, in the sheep safety study, no significant toxicological effects were observed 
although modest increases in inflammatory infiltrates in the vaginal epithelia were 
considered to be TFV- and/or ring-related.   
 
 
4.5.1 In vitro studies 
The steady-state in vitro TFV release rate increased with HPU equilibrium 
swelling, thus allowing simple modulation of the release rate by selecting an HPU with 
appropriate equilibrium swelling. Since TFV is virtually insoluble in the non-swelling 
polymer phase (6), increased water presence allowed for the water-soluble TFV to 
dissolve and diffuse through the aqueous phase of the hydrated polymer. The lower 
durometer 35 wt% swelling HPU released approximately 10 mg/day TFV for 90 days 
with time-independent IVR mechanical stiffness similar to NuvaRing, which was utilized 
as a benchmark for mechanical stiffness due to its high user acceptance and extensive 
safety record in women (43).  
Glycerol incorporation in the IVR core formulation yielded several benefits over 
100% TFV powder including easier lumen filling and increased TFV density to maximize 
TFV loading. Although TFV comprised approximately 36% of the ring’s total mass, the 
ring mechanical stiffness remained unchanged throughout the 90 day duration even after 
the majority of the TFV was released. This unique performance attribute was due to the 
semisolid core whose presence or absence did not significantly impact the overall ring 
elasticity, in contrast to the solid core TFV matrix IVR that was initially quite stiff  but 
softened upon hydration and as TFV was released (6).  
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Glycerol also acted as an osmotic agent to rapidly draw water into the TFV-
loaded core and nearly eliminated the time to steady-state TFV release. Following initial 
HPU hydration, we hypothesized that the low amount of water at the inner surface of the 
HPU lumen mixed with the high concentration of glycerol present, resulting in a large 
inward osmotic driving force since glycerol and water are infinitely miscible. Following 
lumen hydration, TFV quickly saturated the aqueous solution to establish a fixed TFV 
concentration gradient across the tubing wall and allow TFV release by membrane-
controlled steady-state diffusion. In the absence of a highly water-miscible molecule in 
the tubing lumen, TFV steady-state release was not achieved after several weeks since 
TFV alone is a relatively poor osmotic agent (~1% w/v solubility in the acidic aqueous 
media utilized) (6).  The excess of undissolved and highly mobile TFV in the tubing 
lumen allowed for true time-independent TFV release until virtually the entire load was 
depleted, thus minimizing drug waste. Conventional solid core polymeric reservoir IVRs, 
such as NuvaRing, create environmental and cost concerns since up to 85% of the initial 
drug load remains in the IVR at the end their planned durations (60).  
Another advantage of the HPU reservoir IVR design is its tunability, where HPU 
equilibrium swelling, cross-sectional diameter, wall thickness, and shore hardness (elastic 
modulus) may be independently varied to achieve the desired TFV loading, TFV release 
rate, and ring stiffness. Commonly utilized silicone IVRs typically demonstrate a lower 
elastic modulus than thermoplastic elastomers and therefore require a wider cross-
sectional diameter and/or the addition of an inert filler excipient to increase ring stiffness 
(12). As increasing IVR dimensions may negatively impact user acceptability (48), we 
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minimized the HPU IVR cross-sectional diameter while still ensuring that the target TFV 
release rate and duration was achieved. 
When accounting for the overall societal costs associated with HIV infection 
including healthcare and inability to work, TFV  1% gel is expected to be quite cost 
effective by South African standards at a projected cost of approximately $5/month (58, 
61). The 90-day reservoir TFV IVR, with an estimated per-unit manufacturing cost of 
less than $1 (personal communication and estimate from ProMed Pharma LLC, 
Plymouth, MN), should therefore cost significantly less per month than the gel. Despite 
its unconventional design, the reported IVR combines existing pharmaceutical and 
medical device materials, techniques, and equipment to minimize associated 
manufacturing costs and ensure affordability in resource-poor countries. From a supply 
chain and distribution perspective, a year’s supply of gel would require significant 
transportation efforts both for the supplier and the end user as compared to 4 rings. In 
addition to lower transportation costs and end-user convenience, the IVR would also 
minimize waste management issues associated with the number of gel applicators and 
packaging required for frequent use. 
 
 
4.5.2 In vivo pharmacokinetics 
In the CAPRISA 004 clinical trial evaluating the TFV 1% gel, women with 
vaginal fluid concentrations greater than 103 ng/mL were significantly more protected 
against HIV infection than women with concentrations less than 103 ng/mL (23). In the 
sheep pharmacokinetic study described in this report, the TFV IVR attained near steady-
state vaginal fluid concentrations at day 1 (106 ng/g or ng/mL), which were 
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approximately 1000 times higher than the clinically protective concentration, and this 
level was maintained for the remainder of the 90 day duration. Vaginal dosing of the TFV 
1% gel both in a controlled clinical pharmacokinetic study previously reported by 
Schwartz et al. (45) and in our sheep gel group demonstrated peak 106 ng/g TFV vaginal 
fluid concentrations several hours post-dose which were equivalent to the observed 
steady-state TFV IVR concentrations.  
Although TFV tissue concentrations were not measured in the CAPRISA 004 
trial, the clinical pharmacokinetic study by Schwartz et al. reported approximately 105 
ng/g peak vaginal tissue concentrations at 2 hours post-dose which plateaued at around 
104 ng/g thereafter (45). Our sheep gel group attained approximately 103 - 104 ng/g tissue 
levels 8 hours post-dose, but were lower at 24 hours post-dose. TFV tissue concentrations 
at 8 hours post-IVR insertion were comparatively lower than 8 hours post-gel dose. 
However, mean TFV tissue concentrations of approximately 104 - 105 ng/g were observed 
at the next sampling time point (day 14) through the remaining dosing duration (day 90) 
which were similar to Cmax gel tissue concentrations. Since tissue biopsy time points 
between 8 hours and 14 days were not collected, it is not known whether similarly high 
tissue concentrations were achieved earlier than 14 days with the TFV IVR. However, 
since vaginal fluid and plasma concentrations were near steady-state by days 1 and 7, 
respectively, it seems probable that near steady-state tissue levels were reached within the 
first several days as vaginal tissue acts as the intermediary compartment for drug between 
vaginal fluid and the systemic circulation (62). The elevated sheep tissue TFV 
concentrations reported herein from the TFV HPU IVR were approximately 1000 times 
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higher than sheep tissue TFV concentrations from an alternative TFV IVR design (35), 
reflecting the nearly 1000-fold greater TFV in vitro release rate from the HPU IVR. 
The mean TFV concentrations in vaginal fluid, vaginal tissue, and plasma in the 
IVR group were similar to or greater than peak concentrations attained in the gel group. 
This is an interesting result considering that the time-averaged daily TFV release from 
the IVR, as determined by residual device extraction, was less than one-half of the daily 
TFV gel dose. The percent of dosed TFV which is absorbed following TFV 1% vaginal 
gel administration has not been reported, but it is likely that a significant fraction is not 
absorbed because the gel leaks out of the vaginal tract (2, 33). The gel more rapidly 
achieved high TFV vaginal and systemic concentrations and therefore may be 
advantageous for coitally dependent, intermittent use where it is applied just prior to sex 
(similar to CAPRISA 004 dosing). Conversely, the IVR may be advantageous when 
women desire a long-lasting, coitally independent, and discreet dosage form.  
It is generally assumed that antiretrovirals should be well distributed throughout 
the vaginal tract to maximize HIV prevention. TFV vaginal fluid and tissue 
concentrations measured proximal and distal to the IVRs’ placement were nearly 
identical over the 90 day period and trended similar to the TFV 1% gel. This finding 
corroborates previous TFV IVR pharmacokinetic studies in sheep where TFV levels 
proximal and distal were indistinguishable (36). Conversely, vaginal biodistribution of 
hydrophobic antiretrovirals delivered from IVRs has been evaluated in women and 
macaques and both studies have shown a higher drug concentration proximal to the ring 
than distal (22, 40). Therefore, if uniform vaginal biodistribution proves necessary, 
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hydrophilic antiretrovirals such as TFV may be better suited for IVR delivery than 
hydrophobic antiretrovirals. 
Reservoir drug delivery devices typically offer near time-independent release of 
molecules given sink conditions are satisfied (25, 42). Time-independent TFV release 
rates were attained by day 2 in vitro, and similarly TFV vaginal fluid concentrations 
stabilized by day 2 in vivo, suggesting that the device was releasing drug in a zero-order 
fashion as expected. Following a 3 - 7 day lag time, TFV plasma concentrations in the 
IVR group were steady for the remaining 90 days with the exception of day 14. It is 
known that hydrophobic compounds can be more rapidly transported across the 
epithelium for systemic absorption than hydrophilic compounds (62), yet there has been 
limited reports of hydrophilic API plasma pharmacokinetics from IVRs, in part due to 
IVR formulation limitations of such APIs as previously discussed. Also, the reported 
TFV IVR did not provide an initial burst of drug as do conventional matrix and reservoir 
IVRs. Nonetheless, a similar plasma concentration-time profile has been observed with 
the contraceptive NuvaRing whereby plasma concentrations of the hydrophobic small 
molecules ethinyl estradiol and etonogestrel peaked approximately 1 week after IVR 
insertion in women (50).  
A significantly higher release rate was observed in vivo than in vitro, which is 
atypical for controlled release devices. Of note is that TFV is an acidic compound, with 
increased aqueous solubility at higher pH. The drug release rate from reservoir IVRs is 
proportional to the dissolved concentration of drug in the tubing lumen (55). Therefore, 
the sheep neutral vaginal pH may increase the dissolved TFV concentration in the IVR 
lumen and thus demonstrate higher TFV flux than in the in vitro pH 4.2 acetate buffer 
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release media. The pH of the healthy human vagina is acidic due to buffering by lactic 
acid-secreting microflora (62). Therefore, future studies in women will be needed to 
determine whether the increased in vivo flux in sheep is also observed in women.  
The 35 wt% swelling HPU TFV IVR demonstrated similar TFV in vivo release 
rates and TFV vaginal concentrations in both sheep studies, albeit the second study did 
not include as many time points, as its primary objective was toxicological evaluation. 
Nonetheless, the studies at separate institutions utilizing two different sheep breeds 
confirmed the ability of the HPU TFV IVR to reproducibly provide elevated and 
sustained TFV vaginal concentrations for up to 90 days.  
 
 
4.5.3 In vivo toxicology 
An efficacious microbicide product must not compromise vaginal barrier 
function. Thinning or disruption of the protective epithelium and/or recruitment of 
susceptible immune cells via an inflammatory response could increase HIV infection, as 
was observed with early HIV prophylaxis trials using surfactants and anionic polymers 
(26, 52, 53). Microbicide IVRs are designed to be present in the vagina for a duration of 
weeks to months, and beyond brief excursions would likely be reinserted or replaced 
throughout a woman’s sexually active life. The potential long-term vaginal effects of an 
IVR and its corresponding influence on HIV prophylaxis are therefore a concern. Bounds 
et al. studied an early version of Femring® that had remarkable mechanical stiffness, and 
it was concluded that the ring contributed to the creation of ulcerative lesions in the 
vagina (5). Subsequently, several large clinical safety studies have evaluated an array of 
medicated and non-medicated IVRs composed of  silicone and ethylene vinyl acetate 
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polymers comprising various dimensions and ring stiffness (14, 27, 41, 43, 47, 59). None 
of these studies found a significant ring contribution in creating epithelial lesions and/or 
altering vaginal microflora when tested for up to 1 year. Furthermore, several marketed 
IVRs have now recorded thousands of women-years of use with favorable safety records 
(16, 43). Polyurethane IVRs have not been clinically evaluated to date, although 
evaluation in pigtail macaque monkeys shows no significant alteration in native 
microflora or mucosal and proinflammatory cytokines when compared to naïve animals 
(22) or animals receiving silicone IVRs (personal communication with J. Smith, Centers 
for Disease Control and Prevention, Atlanta, GA).  
Care was taken at the onset of product development to utilize materials that 
possess strong evidence of safety in humans. Medical-grade polyurethanes have 
demonstrated long-term biocompatibility in many biomedical and drug delivery 
applications (28). Of the potential water-miscible excipients, glycerol was utilized, as it is 
generally recognized as safe by the Food and Drug Administration and is one of the most 
commonly used excipients in vaginal formulations (17) including in the clinically 
efficacious TFV 1% gel (1). The overall amount of glycerol in the TFV IVR (825 mg) is 
approximately equivalent to that incorporated in a single dose of the TFV 1% gel (800 
mg), which demonstrated no significant adverse events in women (1, 32). Greater than 
95% of the glycerol was released from the ring in the first 3 days (data not shown). Over 
a 90 day duration, the TFV IVR would deliver significantly less glycerol vaginally than 
the gel which could be dosed up to twice daily.  
Following 28 or 90 days of treatment with a single IVR, no signs of systemic 
toxicity were observed. Minimal cellular debris or bacterial adhesion was found on the 
85 
 
IVR surface after 28 days in sheep as observed by electron microscopy (data not shown). 
Slight but notable changes in the microscopic pathology of the cervicovaginal epithelium 
were found to be associated with the presence of the placebo and TFV IVRs. These 
histopathological findings also correlated with a mild increase in the vaginal irritation 
potential of the IVRs. Though sheep have been used for the systemic safety evaluation of 
microbicide IVRs (37) and to evaluate the effects of vaginal gels on the epithelium (56), 
they are yet to be considered a validated model for the testing of vaginal microbicide 
products and therefore the significance of the results reported here may still be unclear.  
Nonetheless, this is the first time, to the best of the authors’ knowledge, in which the 
vaginal irritation scoring methodology developed by Eckstein et al. (9) has been applied 
to sheep. As the methodology is relatively simple to perform, continued evaluation of 
vaginal irritation scoring of clinically tested microbicide products may help to define its 
usefulness as a nonclinical vaginal irritation model.  
The modest increase in leukocytic infiltration in the vaginal epithelium of sheep 
receiving IVRs (placebo and to a greater extent TFV IVRs) warrants further evaluation to 
determine any potential effects on long-term safety and efficacy. The optimal TFV daily 
dose to deliver from a ring is unknown as dose ranging efficacy studies with any vaginal 
prophylactic TFV dosage form have not been performed. The reported TFV IVR 
demonstrated approximately 10 mg/day in vitro release rates which correspondingly 
maintained vaginal TFV concentrations similar to or exceeding peak concentrations with 
the TFV 1% gel. Future nonhuman primate and human toxicity and efficacy studies will 
aid in determining an optimal TFV daily dose that provides maximum efficacy. The TFV 
release rate from this flexible IVR platform may be easily modulated to attain this desired 
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dose by varying the HPU equilibrium percent swelling and/or tubing cross-sectional 
dimensions (as reported herein and in Chapter 5). 
Sheep possess several additional advantages and limitations for HlV prophylactic 
IVR safety and pharmacokinetic evaluation beyond that mentioned above (for a more 
detailed discussion of the female sheep reproductive anatomy and physiology, the reader 
is referred elsewhere (10, 11, 13)). In contrast to the more commonly utilized rhesus and 
pigtail macaque nonhuman primates  (18, 22, 30, 38), most sheep breeds demonstrate 
body mass and vaginal anatomical dimensions similar to women, allowing for human-
sized IVR testing and avoidance of scaling issues when extrapolating ring mechanics, 
drug dosing, biodistribution, and pharmacokinetics (35, 36). Although sheep are not 
susceptible to infection by related immunodeficiency viruses, they are more affordable 
and easier to acquire than nonhuman primates. Similar to humans, the sheep vaginal 
epithelium is stratified squamous and thus is pertinent for toxicological irritation studies 
such as that described herein. The vaginal microflora species and vaginal fluid pH of 
sheep and women is generally different, although large variation in both variables exists 
in both populations (29, 31, 57).  
Sheep are seasonal breeders with a shorter estrous cycle (approximately 17 days) 
than women, which may potentially alter drug pharmacokinetics via changes in vaginal 
epithelium thickness and permeability (33, 39). The estrous cycle was not monitored or 
controlled in this study, although over the IVR and gel test duration the animals would 
have undergone approximately 5 and 1 complete estrous cycles, respectively. Generally, 
vaginal fluid, vaginal tissue, and plasma concentrations in the IVR group (individual and 
mean) increased or were steady with time, and did not appear to follow any cyclical 
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trend. Conversely, concentrations in the gel group generally decreased with time. As a 
result, the hormonal cycle appeared to not significantly influence local or systemic TFV 
pharmacokinetics although further studies may consider monitoring this potential effect 
in greater detail. 
In summary, we believe that the HPU reservoir IVR provided sustained sheep 
TFV vaginal fluid, vaginal tissue, and plasma concentrations for 90 days which were 
similar to peak concentrations in women using the TFV 1% gel. The TFV IVR showed 
no attributable toxicological effects although a modest increase in inflammatory 
infiltration of the vaginal epithelium was observed with the placebo IVR and to a greater 
extent with the TFV IVR when comparing to the sham control. While human studies are 
needed to confirm the safety, pharmacokinetics, and potential efficacy of this new HPU 
reservoir IVR design, the IVR achieved what are likely prophylactic concentrations for 
the 90 day study duration. This IVR design addressed conventional IVR limitations in 
delivering significant quantities of drug for sustained duration, and further demonstrated 
flexibility in modulating drug release kinetics and ring mechanical properties. Altogether, 
these results support further exploration of the HPU reservoir IVR as a sustained TFV 
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Table 4.1. Sheep safety study design.  
 
Group Treatment Dose Number of Animals 28 days 90 days 
1 Control Sham dose only 5 5 
2 Placebo IVR 1 IVR/animal 5 5 

































Table 4.2. Mean (standard deviation) pharmacokinetic parameters for the TFV IVR and 
TFV gel. 
 
Parameter Group 1 (IVR) Group 2 (Gel) 
Vaginal Fluid 
 Proximal Distal Proximal Distal 
Tmax (hr)* 504 72 336 8 
Cmax (ng/g) 2.4E+7 (3.9) 5.1E+6 (2.5) 1.1E+6 (0.8) 9.0E+5 (6.2) 
AUC0-90 days (ng·hr/g) 1.3E+10 (2.2) 2.4E+9 (2.2) NA NA 
Vaginal Tissue 
 Proximal Distal Proximal Distal 
Tmax (hr)* 1.1E+3 2.2E+3 8 8 
Cmax (ng/g) 4.7E+4 (2.6) 8.8E+4 (9.7) 2.7E+4 (2.8) 8.1E+3 (11.2) 
AUC0-90 days (ng·hr/g) 5.1E+7 (2.0) 4.7E+7 (3.6) NA NA 
Plasma 
Tmax (hr)* 336 2 
Cmax (ng/mL) 31.3 (8.3) 46.8 (20.8) 
AUC0-90 days (ng·hr/g) 3.2E+4 (0.6) NA 
*Median Tmax reported. For the gel group, refers to time post-1st dose (336 hours = pre-

















Table 4.3. Study 2 TFV vaginal fluid, vaginal tissue, and plasma concentrations from the 






Mean SD 1 2 3 4 5 
Vaginal fluid (ng/g) 
Proximal, Day 
28 5.8E+6 5.6E+6 9.6E+6 7.9E+6 4.8E+6 6.8E+6 2.0E+6 
Distal, Day 28 1.8E+6 1.3E+7 1.4E+6 4.4E+6 1.9E+6 4.6E+6 5.0E+6 
Proximal, Day 
90 3.0E+6 1.7E+6 3.6E+5 1.6E+6 1.4E+6 1.6E+6 9.5E+5 
Distal, Day 90 3.3E+6 1.5E+6 2.1E+5 1.5E+6 1.3E+6 1.6E+6 1.1E+6 
Vaginal tissue (ng/g) 
Proximal, Day 
28 8.1E+4 4.7E+3 6.1E+3 7.6E+3 4.0E+3 2.1E+4 3.4E+4 
Distal, Day 28 6.7E+4 2.5E+4 9.2E+3 1.7E+4 4.5E+3 2.4E+4 2.5E+4 
Proximal, Day 
90 7.8E+3 2.0E+3 1.4E+3 1.3E+3 1.7E+3 2.9E+3 2.8E+3 
Distal, Day 90 3.6E+3 1.4E+3 6.7E+2 5.5E+3 1.6E+3 2.5E+3 2.0E+3 
Plasma (ng/mL) 
Day 28 23.8 18.0 29.4 24.0 31.7 25.4 5.4 
Day 90 11.0 2.0 * 8.1 15.6 7.3 6.4 




























Figure 4.1. Diagram of the sheep pharmacokinetic study design/dosing protocol for TFV 
















Figure 4.2. (A) Comparison of HPU IVR with commercially available IVRs: Estring 
(left), TFV IVR with novel HPU reservoir design (center), and NuvaRing (right). (B) 
Diagram of HPU IVR with 55 mm outer diameter (OD), 0.7 mm wall thickness (W), and 








Figure 4.3. (A) The in vitro TFV daily release rate as a function of time from prototype 
IVRs composed from different swelling HPU tubing whose lumen contained 65/33/2 
wt% TFV/glycerol/water (solid symbols) or TFV only (open triangles). (B) Percent 
cumulative release as a function of time for 60 and 35 wt% swelling HPUs with glycerol 





Figure 4.4. In vitro TFV release rate (A) and the force required for 10% compression of 
the ring diameter compared to NuvaRing (B) for the softer shore hardness 35 wt% 
swelling HPU IVRs composed of 65/33/2 wt% TFV/glycerol/water (IVRs were 








Figure 4.5. Proximal and distal TFV vaginal fluid concentrations for TFV IVR (A) and 
















Figure 4.6. Proximal and distal TFV vaginal fluid washout concentrations following IVR 








Figure 4.7. Proximal and distal TFV vaginal tissue concentrations for TFV IVR (A) and 







Figure 4.8. TFV plasma concentrations for TFV IVR (A) and TFV gel (B). TFV IVR and 
gel plasma levels were less than LOQ at 24, 48 and 72 hours post-IVR removal and 
following the 28th gel dose (only 24 hr post-gel dose is shown). Data represent mean ± 
















Figure 4.9. Representative micrographs of H&E stained posterior vaginal tissue after 1 or 


















Figure 4.10. Sheep vaginal irritation scores (on a scale of 0 – 16) after 28 or 90 days of 
treatment with TFV or placebo IVRs or sham control. *Values for TFV IVRs were 









ENGINEERING OF A NEW INTRAVAGINAL RING  




The hydrophilic antiretroviral agent tenofovir (TFV) recently exhibited partial 
effectiveness against HIV when used prophylactically in a short-lasting vaginal gel 
formulation. TFV reservoir intravaginal rings (IVRs) were designed and tested to offer a 
long-lasting and coitally dissociated alternative dosage form. The IVRs were fabricated 
from hydrophilic polyurethane tubing with varying equilibrium aqueous swelling and 
wall thickness, and the tubing lumens were filled with a high-density semisolid paste 
primarily comprising TFV and glycerol. Release of TFV in vitro followed geometry- and 
swelling-dependent zero-order kinetics for up to 90 days. The steady-state TFV release 
rate and amount of water partially bound to the hydrated polymer displayed similar 
exponential decay kinetics when the IVRs were stored at 40°C prior to in vitro release 
testing, but eventually stabilized. The lead ring design and composition was well 
tolerated in sheep and the time-averaged mean in vivo TFV release rate was 
approximately 75% greater than the 13 mg/day observed in vitro. Overall, we designed 
and characterized a physically and chemically stable IVR platform to provide tunable, 
time-independent TFV release and ring mechanical stiffness for up to 90 days which may 
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The human immunodeficiency virus (HIV) infects over a thousand women in sub-
Saharan Africa every day, motivating the development of vaginal prophylactic 
technologies to protect women against the sexual transmission of HIV (37). Despite poor 
user adherence, a short-lasting gel delivering 40 mg of the antiretroviral agent tenofovir 
(TFV) was 39% effective at preventing HIV infection in women when vaginally applied 
before and after coitus (1). HIV prophylaxis was positively correlated with TFV vaginal 
concentrations and user adherence (13), suggesting that TFV dosage forms that provide 
long-term elevated concentrations and increased user adherence will improve the 
effectiveness of TFV (33, 39). Since dose-ranging studies have not been performed in 
women to associate the vaginal dose of TFV with the vaginal fluid and tissue 
concentrations and/or effectiveness against HIV, the optimum TFV gel dose for safety 
and efficacy is unknown. Similarly, optimum TFV doses are unknown for long-lasting 
dosage forms such as intravaginal rings (IVRs), which possess a differing dosage 
regimen and are likely to have different vaginal drug distribution and absorption. As a 
result, we estimate that an optimum IVR dose will be within the same order of magnitude 
as that of the clinical TFV 1% gel. Unfortunately, TFV has limited solubility in 
conventional hydrophobic IVR polymeric platforms, including silicone and ethylene 
vinyl acetate. As the drug release rate from an IVR is linearly dependent on the molecular 
concentration dissolved in the polymer (14), it is not surprising that conventional IVRs 
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deliver micrograms of TFV per day, which is orders of magnitude less than the clinical 
gel (34).   
Hydrophilic polyurethane (HPU) matrix IVRs exhibit promising TFV fluxes that 
can be configured to release from 1 to 50 mg/day because of the water absorption of HPU 
and the subsequent aqueous-mediated dissolution and diffusion of TFV through the 
hydrated polymer (4, 12). Despite the increased TFV flux compared to conventional 
IVRs, the in vitro TFV release rate and the mechanical stiffness of the ring steadily 
decrease by approximately 10- and 3-fold, respectively, over a 90-day period (4). The 
apparent square-root of time cumulative drug release kinetics are an inherent 
characteristic of matrix IVRs because the drug depletion from a cylindrical IVR cross-
section begins at the outer edge and moves inward with time, resulting in a longer 
diffusional distance for the drug to reach the IVR surface (20). Similarly, a loss in ring 
stiffness occurs as the crystalline dispersed TFV, present at up to 20 wt%, elutes from the 
IVR and creates a lower modulus polymer matrix. The comparatively high TFV flux at 
early time and low TFV flux at long time is undesirable because it could result in local 
toxicity and sub-prophylactic concentrations, respectively. The TFV-matrix IVR 
exhibited decreasing TFV vaginal concentrations with time in nonhuman primates 
(unpublished work) that were similar to that observed in vitro. Likewise, time-dependent 
IVR stiffness could have multiple undesirable effects, including difficulty during 
insertion and removal, ring expulsion from the vaginal tract, and biocompatibility (29). 
An unconventional semi-solid reservoir HPU IVR may achieve the goal of time-
independent mechanical stiffness and milligrams-per-day extended drug release. In 
particular, IVRs with HPU reservoir tubing offer a wide design space because changing 
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such variables as the wall thickness, cross-sectional diameter, HPU elastic modulus, HPU 
percent swelling, and lumen composition could allow the simultaneous optimization of 
the IVR mechanical properties, lumen volume, and TFV flux. The release rate of a drug 











where L is the cylinder length, D is the diffusion coefficient in the wall, K is the partition 
coefficient between the membrane and the core, ΔC is the concentration gradient across 
the membrane, and ro and ri are the cross-sectional outer and inner radii, respectively. 
The ring dimensions and the drug diffusion coefficient in the rate-controlling membrane 
polymer may therefore be modulated to achieve the desired drug release rate. However, 
the ring design must also consider the IVR stiffness, which may directly influence its 
ability to be inserted and retained in the vaginal tract without disrupting the vaginal 
mucosa or being expelled (7, 16, 29, 42). The force required to mechanically compress an 









 where E is the elastic modulus, R is the ring outer radius, and Y is the reduction in ring 
outer diameter. Therefore, altering the ring dimensions and the elastic modulus of the 





release rate and the mechanical stiffness of the ring. Furthermore, changes in the cross-
sectional dimensions will also impact tubing kinking, which is not considered in the 
mechanical equation above. Tubing that is axially flexed will collapse (i.e., kink) when a 
critical bend radius is achieved, with further flexural deformation resulting in noticeably 
reduced mechanical stiffness. The critical bend radius of elastic tubes under pure bending 











where v is Poisson’s ratio and w is the tubing wall thickness (ro- ri). The implications of 
tubing kinking as it pertains to IVR performance will be discussed in greater detail 
below. 
The temperature- and time-dependent microphase separation of the hard and soft 
segments of polyurethane imparts unique physical properties, including high elasticity yet 
thermal processability (36). Generally, the hard and soft segments of polyurethane 
demonstrate miscibility at higher temperatures (i.e., during thermal processing such as 
hot-melt extrusion), which coincides with the disruption of the crystallinity in the hard 
segment (26, 36). Post-processing, lower storage temperatures result in the immiscibility 
of the hard and soft segments, leading to microphase separation and the crystallization of 
the hard segment. Polyurethanes have received little attention as commercial drug 
delivery products, partly because conventional oral delivery applications prefer polymers 
that rapidly dissolve in aqueous media. Furthermore, polyurethanes typically rely on 




pharmaceutical products until recently (28). A lack of knowledge about the polyurethane 
structure-property relationships pertaining to drug delivery is apparent when searching 
Scifinder® for “polyurethane phase separation” and “polyurethane phase separation 
drug,” which yield 1119 and 3 results, respectively (date of search: 7/10/2012). Although 
extensive work over the past half-century has advanced the understanding of the 
microphase separation kinetics of polyurethane (19), no peer-reviewed literature has 
reported its potential impact on the physical stability of a polyurethane drug product (i.e., 
drug release kinetics as a function of storage time). We recently reported a 90 day HPU 
reservoir IVR that exhibited steady-state TFV in vitro release rates of 10 mg/day and 
sustained TFV in vivo vaginal concentrations that were similar to or exceeding the peak 
concentrations of the clinically effective TFV 1% vaginal gel (see Chapter 4). We report 
herein the observation of a solution to the physical instability of the initial IVR prototype, 
specifically regarding the decreased steady-state TFV in vitro release rates as a function 
of IVR storage time. Upon achieving a physically stable formulation, extensive 
engineering and characterization of the finalized IVR design was also performed. 
 
 
5.3 Materials and Methods  
5.3.1 Materials 
Tecophilic® HP-60D-35, HP-60D-60, and HP-93A-100 hydrophilic aliphatic 
polyether urethane (HPU) grades, hereby referred to as HPU-35, HPU-60, and HPU-100, 
respectively, were purchased from Lubrizol Advanced Materials (Wickliffe, OH). The 
manufacturer-specified percent swelling in water at 25°C was 34.3, 51.3, and 94.0 wt% 
for HPU-35, HPU-60, and HPU-100, respectively. Tenofovir monohydrate was supplied 
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by CONRAD (Arlington, VA). USP-grade glycerol and water were purchased from 
Spectrum Chemical (New Brunswick, NJ). All solvents and reagents were ACS grade 
unless otherwise noted. 
 
 
5.3.2 IVR fabrication 
HPU pellets were dried overnight at 150°F in a compressed air microdryer with a 
10 pound hopper (Dri-Air, East Windsor, CT) to a moisture content of less than 0.05 
wt%, as verified using a Karl Fisher Titrator (Mettler-Toledo, Columbus, OH). The dried 
pellets of each grade were used individually. In addition, HPU-60 and HPU-100 were 
physically mixed at wt/wt ratios of 75/25, 50/50, and 25/75 (hereby referred to as HPU-
B1, HPU-B2, and HPU-B3, respectively). The HPU pellets were fed into a 3/4 inch 
single-screw extruder attached to an advanced torque rheometer drive (C.W. Brabender, 
South Hackensack, NJ) with a tubing crosshead (Guill Tool, West Warwick, RI). The 
extruder heating zone temperatures varied with the HPU grade and blend, with barrel 
temperatures (zones 1-3) ranging from 150-180°C and tubing crosshead tip and die 
temperatures (zones 4 and 5) ranging from 130-150°C. The extrudate leaving the tubing 
crosshead was drawn using a CPC2-12 combination puller/cutter (Conair, Cranberry 
Township, PA) to create final tubing products with a 5.5 mm cross-sectional diameter. 
Various crosshead tips were inserted to create 4 tubing wall thicknesses. The final wall 
thickness and concentricity measurements were made using an optical microscope and a 
38DLP ultrasonic thickness gauge with a 20 MHz M316-SU F = 0.75" transducer 
(Olympus NDT, Waltham, MA). The final tubing wall thicknesses, measured at every 90 
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degrees of cross-sectional rotation, were 0.68 ± 0.02, 0.87 ± 0.02, 1.02 ± 0.02, and 1.21 ± 
0.02 mm (mean ± SD, N = 3 tubes).  
The extruded tubes were cut to 162-171 mm in length (depending on the tubing 
wall thickness), and one tubing end was sealed using an induction welder (PlasticWeld 
Systems Inc., Newfane, NY) equipped with a DuPont 857G (Wilmington, DE) reinforced 
polytetrafluoroethylene-coated stainless steel bonding die (Industrial Fluoro-Plastics, 
West Jordan, UT). TFV was mechanically milled using a M20 universal mill (IKA 
Works, Wilmington, NC) and sieved to less than 425 μm with an average aggregative 
size between 75-180μm. The TFV, glycerol, and water were mixed at a 65/33/2 wt% 
ratio using a Hobart mixer with a “B” beater attachment (Troy, OH) and back-filled into 
the tubing using a semicustomized model 2400 medical-grade high-pressure hydraulic 
filling system (Dymax, Torrington, CT). The semisolid formulation included 2% water to 
increase its processable lifetime by reducing its viscosity (i.e., the hydraulic filling 
system could extrude the water-containing formulation for a longer time after it was 
prepared). Each tube was filled with 1.4-2.5 g of the semisolid formulation (depending on 
the extrudate wall thickness and corresponding lumen volume), resulting in 0.9-1.6 g of 
TFV per IVR (the tubes were weighed before and after filling). Alternatively, the HPU-
35 tube lumens with 0.68-mm-thick walls were manually filled and packed with TFV 
alone to achieve 1.6 g of TFV per IVR. After the lumens were filled with either 100% 
TFV or the 65/33/2 wt% TFV/glycerol/water mixture, the second end of the tubing was 
sealed in the same manner as the first and the resultant 5-mm-long hermetically sealed 
ends were welded together using a second induction welder equipped with a stainless 
steel split die. The resultant IVR was placed in a custom-machined 12 cavity aluminum 
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mold to shape-anneal the IVRs into a circular conformation and minimize tube kinking. 
Water heated to 65°C was circulated through the mold for 15 min, followed by 10°C 
water circulation for 5 min. After the shape annealing, the IVRs were either tested under 
various experimental conditions or inserted into foil-lined, moisture-impermeable 
pouches (LPS Industries, Moonachie, NJ) and heat-sealed using an impulse sealer set at 
155°C, recycle setting = 3, and sealing setting = 7 (AIE Inc, Whittier, CA). All of the 
IVR formulations that were fabricated and tested are listed in Table 5.1. 
 
 
5.3.3 In vitro release and mechanical testing 
The in vitro TFV release kinetics and the IVR mechanical stiffness were 
evaluated for up to 90 days as described previously for TFV-matrix IVRs (4, 12). Briefly, 
IVRs were immersed in 25 mM sodium acetate buffer (pH 4.2) and the volume (50-200 
mL) was adjusted as needed to maintain sink conditions (the drug concentration never 
exceeded one-tenth of the maximum solubility). IVRs were placed in a 37°C orbital 
shaker set at 80 rpm. The release medium was replaced every 24 h and sampled 
periodically to quantify the TFV content via HPLC. To calculate the time-averaged 
steady-state TFV release rates, the amounts of TFV released on days 5, 7, 10, and 14 
were averaged because the TFV release kinetics beyond day 3 were generally zero-order. 
The TFV release rates from the equilibrated HPU-B1 IVRs as a function of wall 
thickness were estimated using Equation 5.1. Because the variables encompassing the 
numerator on the right side of Equation 5.1 were constant for HPU-B1, the 
experimentally determined TFV release rate for the 0.68 mm wall thickness was 
multiplied by the corresponding ln(ro/ri) to determine the constant. This constant was 
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then applied to the 0.85, 1.02, and 1.21 mm wall thicknesses to estimate their 
corresponding TFV release rates. Before and during the release study, the IVR stiffness 
was measured by compressing the IVRs 10% of their initial outer diameter using a 
custom-machined aluminum probe and an Instron 3342 uniaxial testing system 
(Norwood, MA). The force corresponding to 10% ring compression was extracted and 
compared across all data sets. To predict the theoretical ring compression values, the 
elastic modulus of HPU-B1 was determined by tensile testing an extruded solid cylinder 
at 1 mm/sec and obtaining a slope from the 1-5% strain, where R2 > 0.995. 
 
 
5.3.4 Weld evaluation and joint robustness 
To confirm sufficient weld integrity following the IVR fabrication, 100 HPU-B1 
rings were hydrated in release media for 7 days and subsequently compressed to 50% of 
the initial ring diameter for 1000 cyclic fatigue cycles at 1/2 Hz using a custom-made 
cyclic fatigue instrument controlled by LabView software (National Instruments, Austin, 
TX). Upon completion of the cyclic fatigue testing, the IVRs were evaluated for joint 
integrity using the Instron 3342 uniaxial testing system and a modified version of the 
ASTM D1414 test method, “Standard Test Methods for Rubber O-Rings”. Briefly, rings 
were elongated at a rate of 5 mm/sec until 100 N of tensile force was reached 
(approximately 100% elongation). The IVR weld was considered acceptable if joint 









5.3.5 TFV content analysis 
Previously reported HPLC methods for determining the TFV concentration were 
used (4, 12). Briefly, 2 μL of sample were injected into a Phenomenex Luna C18 5 μm, 
150 x 4.6 mm column attached to an Agilent 1200 series HPLC with a diode array 
detector and autosampler. Two separate chromatography methods were used for the 
release studies and the chemical stability studies. For the release studies, a 15 min 
gradient method was used to elute the TFV, which began with 100% mobile phase A 
(potassium phosphate buffer, pH 6.0) and ended with 100% mobile phase B 
(acetonitrile/potassium phosphate buffer, pH 6.0). The flow rate was 1.5 mL/min, and 
TFV was detected at 260 nm with an average retention time of 7 min. For the chemical 
stability studies, similar chromatographic conditions were used, with the exception that a 
45 min gradient was run to ensure the separation of potential contaminants or degradation 
products.   
 
 
5.3.6 Quantification of IVR TFV content 
TFV was extracted from the IVRs for content analysis following fabrication or in 
vivo or in vitro release testing. The IVRs were cut into short, 1 cm segments, and all of 
the segments were placed in a 50 mL volumetric flask with 100 mM phosphate buffer to 
completely dissolve the TFV. Following the TFV dissolution, the volumetric flask was 
filled to the 50 mL volume mark, the polymer segments were removed, and an aliquot of 
the concentrated solution was volumetrically diluted and analyzed for TFV content by 
HPLC, as described above. The TFV percent recovery was calculated by normalizing the 
recovered TFV amount by the amount recovered in unused and unstored rings. 
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5.3.7 Chemical and physical stability testing 
IVRs in heat-sealed pouches were placed in a temperature- and humidity-
controlled chamber (Caron, Marietta, OH) set at 40°C/75% relative humidity. The IVRs 
were stored for various durations, after which the chemical and/or physical stability was 
tested. To test the physical stability, the IVRs were subjected to 14 day release testing as 
described above to determine any change in the TFV steady-state release values. To test 
the TFV chemical stability in the formulation, the TFV was extracted from the stored 
IVRs as described above. To determine whether the TFV release rate changes were 
caused by changes in the HPU molecular weight, the IVR lumens of the stored IVRs 
were longitudinally bisected and the lumen contents were physically removed by 
thoroughly wiping the tubing surface with Kimwipes to remove any surface TFV or 
glycerol. The HPU molecular weight was then determined as described below. 
 
 
5.3.8 HPU molecular weight analysis 
Approximately 50 mg of HPU sample was weighed, added to a 10 mL volumetric 
flask, and dissolved overnight in dimethylacetamide with 10 mM lithium bromide (to 
prevent polymer aggregation). Gel permeation chromatography was performed using an 
Agilent 1100 series chromatograph equipped with a BI-DNDC refractive index detector 
(Brookhaven Instruments, Holtsville, NY) and a PLgel 10 μm Mixed-B LS column. The 
mobile phase consisted of 10 mM lithium bromide in dimethylacetamide, and the flow 
rate was 0.75 mL/min. The samples were filtered through 0.45 μm PTFE filters and 
injected using a 100 μL injection volume loop. Monodisperse polystyrene standards were 
dissolved at 1 mg/mL in 10 mM lithium bromide in dimethylacetamide and used to create 
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a universal calibration curve with a linearity greater than 0.999. The Mark-Houwink-
Sakurada constants of K = 1.4x10-4 and α = 0.68 were obtained from the literature (6).  
 
 
5.3.9 HPU IVR swelling measurements 
The swelling measurements of the HPU IVRs were made after the completion of 
the TFV release studies. The IVRs were cut on either side of the joint, and the remaining 
TFV was flushed from the joint and lumen using deionized water. After 1 week of 
equilibration in the release medium at 20°C, Kimwipes were used to dry the exterior joint 
and tubing surface and 60 psi of air was used to remove water from the tubing lumen. 
Any residual moisture in the joint was removed using cotton swabs. The dried joint and 
tubing were then weighed, and the percent swelling was calculated using the recorded 
mass of the tube prior to the IVR fabrication. The tubes were then maintained at 37°C for 
1 week to measure swelling at the in vitro release temperature using the same procedure 
as described for 20°C. The drying and weighing procedures were performed in less than 
30 sec to avoid temperature- and time-dependent changes in percent swelling. 
 
 
5.3.10 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) scans of hydrated HPU were performed 
to determine the state of water in the hydrated HPU. Scans were run on a Q200 DSC (TA 
Instruments, New Castle, DE) equipped with a refrigerator cooling system, autosampler, 
and 50 mL/min nitrogen purge. Prior to sample analysis, the enthalpy of fusion and peak 
onset temperature of pure indium were confirmed. The hydrated HPU IVRs that had first 
undergone various storage conditions, in vitro release testing, and subsequent 20°C 
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swelling measurements (as described above) were scanned by DSC. Biopsy punches (5 
mm) were used to cut cylindrical discs from the hydrated tubing. The hydrated HPU 
discs, ranging from 15 to 20 mg, were weighed and added to aluminum Tzero pans and 
sealed with hermetic lids. Scans were performed from 25°C to -80°C at 5°C/min. After a 
1 min equilibration at -80°C, the temperature was then returned to 25°C at 5°C/min. 
Universal Analysis software (TA Instruments, New Castle, DE) was used for all parts of 
the thermogram analysis, including peak integration. The enthalpy of freezing and 
melting were calculated as joules per gram of dry polymer (the dry polymer mass was 
back-calculated using the IVR swelling measurements from above). 
 
 
5.3.11 In vivo IVR evaluation 
The final ring composition and design was tested in a sheep model (Ovis aries) to 
determine the ring retention and an in vivo TFV release rate. All sheep were housed under 
appropriate conditions according to the Guide for the Care and Use of Laboratory 
Animals. The University of Utah animal facility is accredited by the Association for the 
Assessment and Accreditation of Laboratory Animal Care (AAALAC, #A3031-01) and 
has an assurance on file with the Office for Laboratory Animal Welfare. Five female 
Columbia crossbred sheep of breeding age (65 - 80 kg) received TFV IVRs under an 
animal protocol approved by the University of Utah IACUC. The IVRs were placed in 
the proximal vagina (near the cervix) of the sheep for 29 days, after which the rings were 
retrieved and residual drug content analysis was performed to determine the amount of 





5.3.12 Statistical analysis 
The data were analyzed using one-way ANOVA and unpaired two-tailed 
Student’s t-test. A p-value below 0.05 was considered statistically significant. R2 values 
were calculated using the Pearson correlation coefficients. 
 
 
5.4 Results  
5.4.1 HPU IVR fabrication and weld evaluation 
Medical-grade hydrophilic polyurethanes of varying percent swelling were hot-
melt extruded to create tubing with a 5.5 mm outer diameter. The tubing lumens were 
filled with 100% TFV or a semisolid mixture of 65/33/2 wt% TFV/glycerol/water and 
induction-welded to create 55 mm outer diameter IVRs (Figure 5.1). To confirm that the 
IVR welding methods were sufficient to prevent joint failure upon HPU hydration and 
ring mechanical stress, 100 hydrated IVRs underwent mechanical cyclic fatigue testing 
followed by tensile testing. All of the rings survived 1000 cyclic fatigue cycles and 100 N 
of tensile force without joint or tubing failure, indicating that the weld failure rate under 
these rigorous testing conditions was below 3% using a 95% confidence interval.  
Qualitatively, the IVRs made from tubing with wall thicknesses less than 0.68 
mm demonstrated tubing kinking when only slightly compressed from their original state 
(less than approximately 35% ring compression), as predicted by a critical bend radius 
above approximately 20 mm (Figure 5.2). In addition, the welding of tubing with thinner 
walls proved to be difficult due to insufficient tubing longitudinal stiffness. As a result, 
0.68 mm was selected as the lower bound for the tubing wall thickness; 1.21 mm was 
selected as the upper bound to achieve a minimum TFV loading of 0.9 g per IVR.   
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5.4.2 TFV release kinetics from unstored IVRs 
HPU-35 IVR lumens that incorporated the water-miscible small molecule 
glycerol established near-steady-state TFV kinetics in vitro by day 3 (Figure 5.3A). 
Conversely, HPU-35 IVRs with 100% TFV in the tubing lumen demonstrated gradually 
increasing in vitro TFV release rates that did not reach steady-state by day 28. The tubing 
lumen was fully hydrated after 24 h for the glycerol-formulated IVRs, whereas the tubing 
lumen was still only partially hydrated at day 28 for the 100% TFV-formulated IVRs. As 
a result, all subsequent IVR testing utilized the lumen formulation of TFV/glycerol/water, 
whereby the steady-state TFV release rate was found to increase with the HPU percent 
swelling (Figure 5.3B, t = 0 storage time). However, when the IVRs were first stored at 
40°C and subsequently subjected to in vitro release testing, they demonstrated lower 
steady-state TFV release rates that decreased as a function of IVR storage time (Figure 
5.3B). The decrease in the steady-state TFV release rates followed exponential decay 
kinetics, eventually plateauing (p = 0.09 between 6- and 8-week storage times for HPU-
B1 IVR, Student’s two-tailed t-test). The time required to attain equilibrium, related to 
the decay constant, increased with the elastic modulus of HPU (elastic modulus of HPU-
35 > HPU-60 > HPU-B1).   
 
 
5.4.3 Chemical and physical stability analysis 
Several experiments were conducted to investigate whether the diminished TFV 
steady-state values after IVR storage at 40°C were a result of chemical and/or physical 
instability in the formulation. The percent recoveries of TFV from IVRs stored for 0, 2, 4, 
and 6 weeks at 40°C were 100.0 ± 2.1, 98.0 ± 0.4, 99.6 ± 2.1, and 98.2 ± 0.8 percent, 
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respectively (mean ± SD, N=3 IVRs/time point), indicating no significant TFV chemical 
degradation (p = 0.34, one-way ANOVA). Similarly, there was no considerable change in 
the molecular weight of HPU after 2 and 8 weeks of IVR storage at 40°C (Table 5.2). 
Therefore, it was concluded that physical changes occurring in HPU during storage 
caused the decreased TFV steady-state flux. To evaluate the potential interaction of 
glycerol with the HPU, the HPU tubing alone (lacking any lumen formulation) and HPU 
tubing immersed in glycerol (no TFV or water) were stored for various times at 40°C and 
subsequently filled with the semisolid formulation to test the in vitro release of TFV. 
Both tubing alone and glycerol-immersed tubing demonstrated reduced but equilibrated 
TFV release rates that were similar to the plateau values observed in Figure 5.3B (data 
not shown). However, the time to equilibrium was significantly shorter for the glycerol-
immersed tubing than for tubing alone, implying that HPU undergoes physical changes 
during storage that are accelerated by glycerol.  
 
 
5.4.4 HPU swelling and water-state 
The percent swelling of the HPU-B1 tubing was measured as a function of the 
IVR storage time to monitor any potential changes in the bulk swelling which could 
influence the TFV release kinetics. The swelling of unstored HPU-B1 IVRs at 37°C 
(after 14 days of in vitro release testing) was 65 wt% but dropped to approximately 55 
wt% after 8 weeks of IVR storage at 40°C, at which point swelling had equilibrated 
(Table 5.3, p = 0.34 between HPU-B1 IVR 6- and 8-week storage time, 2-tailed Student’s 
t-test). The most significant drop in swelling occurred between 0 and 2 weeks of IVR 
storage, which paralleled the considerable drop in the TFV release rate. The swelling was 
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approximately 2-4% higher at 20°C than at 37°C regardless of the IVR storage time. As 
the state of water in the hydrated HPU (bound, partially bound, or free) may influence the 
TFV release rate, DSC thermograms were also generated for the hydrated IVRs 
postrelease which had first been stored for various times at 40°C. Unstored HPU-B1 
IVRs exhibited melting endotherm and freezing exotherm water peaks for both free and 
partially bound water (9, 21). All endotherms and exotherms decreased in height and 
peak area with increasing IVR storage time (Figure 5.4A and Table 5.3), with peak onsets 
shifting to lower temperatures. Peak 2, representing the freezing point of partially bound 
water, changed most dramatically, as it was initially large but was no longer detectable 
after 6 weeks of storage for the HPU-B1 IVR. The corresponding enthalpy of freezing for 
peak 2 dropped significantly with increasing IVR storage time and followed exponential 
decay kinetics that were indistinguishable from those of the steady-state TFV release rate 
for HPU-B1 (Figure 5.4B, the decay constant for peak 2 and the steady-state TFV release 
rate were 5.7 and 5.6, respectively). In comparison, peaks 1 and 4, corresponding to the 
freezing and melting of free water, respectively, showed only slight reductions in the 
enthalpic peak area as a function of storage time. Peak 3, corresponding to the partially 
bound water enthalpy of melting, was not calculated because the extremely broad peak 
shape prevented quantification.  
 
 
5.4.5 Final design selection and in vitro characterization 
After confirming that equilibrium was achieved for each HPU (i.e., no significant 
decrease in the TFV release rate or HPU swelling between two storage time points), the 
TFV steady-state release rate for each HPU IVR was plotted as a function of its 
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equilibrium swelling percentage (Figure 5.5A). As expected, the TFV release rate 
increased with the equilibrium swelling percentage, ranging from 3-27 mg/day. However, 
the curve was nonlinear, following a trend whereby the TFV release rates from the 
higher-swelling HPUs were disproportionally greater. To understand the potential 
underlying mechanism, the equilibrated HPU IVRs were also evaluated by DSC. The 
enthalpic difference of the free water (peaks 1 and 4) between HPU-35 and HPU-B3 was 
less than 5-fold (Table 5.4) despite their 10-fold difference in steady-state release rate. 
The free water enthalpy of melting (peak 4) was linearly related to the equilibrium 
percent swelling (Figure 5.5B). In comparison, the enthalpy of freezing (peak 2) showed 
significant differences between the HPU swelling types: it was only detectable in the 
equilibrated HPU-B2 and –B3 IVRs, both of which exhibited much higher TFV release 
rates than the lower-swelling HPUs.  
HPU-B1 was further investigated with various tubing wall thicknesses to 
determine the TFV release rate dependence on ln(ro/ri) as predicted by Equation 5.1, the 
IVR mechanical stiffness dependence on ri4 as predicted by Equation 5.2, and IVR tube 
kinking dependence on ro2/ w as predicted by Equation 5.3. The experimental equilibrium 
TFV release rate (post-IVR storage) followed the general trend predicted by ln(ro/ri) 
although a slight deviation was observed at the terminal phase (Figure 5.6, R2 = 0.98). To 
predict the IVR stiffness at 10% ring compression, the elastic modulus of HPU-B1 was 
measured as 19.3 ± 0.4 MPa (mean ± SD, N = 3). The force required to achieve 10% ring 
compression for the four different wall thicknesses was then estimated using Equation 
5.2. The experimental force values were determined using unfilled HPU-B1 IVRs to 
eliminate any potential mechanical contribution from the semisolid lumen formulation. 
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Despite a slight bias, the predicted and experimental force values were comparable with 
an R2 value of 0.84 (Figure 5.7). IVR tube kinking was qualitatively determined as the 
exact point of tube kinking is poorly defined and could not be accurately quantified. 
However, the approximate point of tube kinking for the four wall thicknesses followed 
the expected trend as predicted in Equation 5.3 whereby the 1.21 mm wall thickness IVR 
did not kink when fully compressed and the 1.02, 0.87, and 0.68 mm wall thickness IVRs 
kinked at approximately 100, 75, and 50% ring compression, respectively. 
The HPU-B1 IVR with a 0.68 mm wall thickness was selected as the lead 
prototype as it achieved an equilibrated (poststorage) TFV release rate that was similar to 
the previous HPU IVR yielding promising results in sheep, possessed the largest core 
volume to maximize the amount of TFV loaded in the reservoir, and exhibited desirable 
mechanical stiffness and tube kinking. The 90 day in vitro release and mechanical 
stiffness was tested for these IVRs after 2 weeks of storage at 40°C because this 
treatment brought the HPU-B1 to near-equilibrium. The TFV release kinetics were time-
independent from day 2 through day 90 (Figure 5.8A). In addition, the IVR mechanical 
stiffness did not change considerably before or throughout the 90 day study period 
(Figure 5.8B) and the required force for ring compression was approximately 10% higher 
compared to the empty HPU IVRs previously tested (Figure 5.7 t = 0). The force required 
for 10% ring compression was approximately 2.4-fold greater than NuvaRing® and only 









5.4.6 In vivo TFV release evaluation 
The IVRs were subsequently tested in sheep to determine the in vivo time-
averaged TFV release rate. The IVRs were constructed from HPU-B1 tubing with a 5.5 
mm cross-sectional diameter and 0.68 mm wall thickness and stored for 2 weeks at 40°C 
as the final manufacturing step. There were no ring expulsions over the 29 day study 
period, and the inspection of the IVRs post-use revealed no issues with the weld integrity. 
The 29-day average in vivo release rate, as determined by residual TFV extraction, was 
22.8 ± 7.0 mg/day (mean ± SD, N=5 sheep), approximately 75% higher than the average 
13 mg/day in vitro release rate for the same lot of IVRs stored for 2 weeks at 40°C 
(Figure 5.8A).  
 
 
5.5 Discussion  
A new reservoir intravaginal ring manufactured from hydrophilic polyurethane 
tubing achieved time-independent TFV release rates and unchanged mechanical stiffness 
for up to 90 days. The design offered flexibility in modulating the drug release rate and 
the ring mechanical properties by adjusting the IVR dimensions, HPU elastic modulus, 
and HPU percent swelling. Attenuated steady-state drug release rates were observed after 
the IVRs were stored at 40°C and were primarily attributed to less partially bound water 
in the hydrated HPU being available for TFV diffusion. The final device design provided 
a ring mechanical stiffness similar to commercial IVRs and release rates of 
approximately 10 mg/day for 90 days after the equilibration of the HPU. In vivo, no rings 
were expelled and the mean drug release rate was 75% greater than the in vitro rate over 
the 29-day study duration.  
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5.5.1 IVR design 
We designed a reservoir HPU IVR that can be modulated to provide controlled, 
milligrams-per-day TFV delivery to offer a long-lasting dosage form as an alternative to 
the clinically effective short-lasting TFV 1% gel. Because IVR mechanics are likely to 
play a critical role in ring insertion, retention, and biocompatibility in the vaginal tract 
(16, 42), we also desired an IVR with time-independent mechanical stiffness that was 
similar to current commercial IVR products. Moreover, we sought to minimize the IVR 
cost to ensure affordability in resource-poor regions, where the HIV pandemic is most 
prevalent. This priority required a ring that could be manufactured for low cost at high 
throughput capacity and could provide sustained TFV delivery for up to 90 days to 
amortize cost. Finally, we attempted to minimize the ring volume to reduce the 
probability of IVR detection during intercourse and the consequent negative impact on 
user acceptability (33). Marketed IVRs typically possess outer diameters of 
approximately 55 mm, with cross-sectional diameters ranging from 4.0 mm to 9.0 mm 
(2). As a result, the IVR outer and cross-sectional diameters in this study were fixed at 55 
and 5.5 mm, respectively. In lieu of evaluating various IVR outer and cross-sectional 
diameters, the HPU swelling and wall thickness were varied to achieve the desired drug 
release rate, dosage duration, and ring mechanical properties.  
IVRs are retained in the vaginal tract via the opposing recoil forces of the 
compressed elastic ring and distended vaginal musculature, resulting in a slightly ovoid 
ring conformation of approximately 10% in the case of NuvaRing® (3, 14). If the tubing 
wall of the HPU IVR were to kink under similar compression values in vivo, the IVR 
recoil force would be diminished and the ring could be displaced or expelled from the 
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vagina. The tubing critical bend radius is inversely proportional to wall thickness 
(Equation 5.3); therefore, a tube that possesses a thicker wall will be more kink-resistant 
but will have a lower lumen volume available for drug loading. We tested HPU tubing 
with wall thicknesses ranging from 0.68 mm to 1.21 mm, as these constraints allowed for 
at least 0.9 g of TFV in the lumen yet did not kink under mild ring compression. The 
force required to compress the IVR to 10% of its initial outer diameter was measured and 
compared to the commercial IVRs NuvaRing® and Estring®, which have established user 
acceptability and safety records and therefore serve as benchmarks for mechanical 
stiffness (30, 31). The 0.68-mm-thick wall of HPU-B1 IVR demonstrated a mechanical 
stiffness that was most similar to the marketed rings and also possessed the highest lumen 
volume. When this IVR was filled with the semisolid formulation and shape-annealed in 
a circular conformation, tube kinking occurred at approximately 75% compression. The 
cross-sectional collapse of the IVR at or near the maximum ring compression values (i.e., 
during user insertion of the ring) may be advantageous as it could ease IVR manipulation 
during insertion yet allow the full recovery of the mechanical stiffness once the IVR is 
inside the vaginal tract due to the reversibility of the tube kinking in the elastomeric 
HPU. 
The measured ring compression force as a function of the wall thickness of the 
HPU-B1 IVR was similar to that predicted by Equation 5.2, with deviations likely due in 
part to geometric inconsistencies in the tubing outer diameter, wall thickness, and IVR 
concentricity. TFV matrix IVRs were recently manufactured under tight dimensional 
tolerances by injection molding, and the subsequent predicted and experimental force 
compression values were nearly identical (4). The predicted force range for the tested 
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tubing IVR dimensions was quite small (1.4 – 1.8 N), increasing the probability of 
experimental error and noise during compression testing. Altogether, the mechanical 
model provided a good estimate of the tubing stiffness for the HPU IVR that may prove 
useful when prototyping devices. When the TFV/glycerol/water HPU-B1 IVRs were 
mechanically tested, their force compression values were similar to Estring® and only 
slightly higher than empty IVRs. Furthermore, the force compression values for HPU-B1 
IVR did not change considerably as a function of time during the in vitro release testing, 
in contrast to the matrix IVR, which demonstrated a 3-fold decrease in ring stiffness after 
90 days (4). This finding highlights the ability of the semisolid lumen formulation to 
provide a negligible contribution to the mechanical stiffness of the ring while achieving a 
high TFV load.  
The in vitro TFV release kinetics for IVRs with and without the osmotic agent 
glycerol were remarkably different. Steady-state TFV release kinetics were attained after 
3 days with the TFV/glycerol/water semisolid lumen formulation, whereas the 100% 
TFV lumen formulation did not achieve steady-state after 28 days. The tubing lumens of 
the glycerol-loaded IVRs were fully hydrated after 24 h in the release medium, whereas 
the 100% TFV-loaded IVRs were not completely hydrated after 28 days, indicating that 
the glycerol functioned as an osmotic agent to rapidly draw aqueous media into the HPU 
lumen and equilibrate the device for steady-state drug release. The measured glycerol 
absorption in the tubing wall of the stored HPU IVRs was approximately 5 wt%, 
suggesting that glycerol was able to diffuse through the HPU tubing wall during storage. 
When the IVR was exposed to aqueous media, a steep glycerol concentration gradient 
across the tubing wall was immediately established because glycerol and water are 
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infinitely miscible. This gradient resulted in a significant water flux into the tubing 
lumen, allowing the subsequent dissolution of TFV and saturation of the lumen aqueous 
media. The excess of undissolved TFV in the core ensured a fixed TFV concentration 
gradient was established across the swollen HPU rate-controlling membrane to produce 
steady-state TFV release kinetics, as described by Equation 5.1. The 100% TFV lumen 
formulation did not achieve steady-state TFV release after 4 weeks because TFV alone is 
a poor osmotic agent (~1% w/v solubility in acidic aqueous media) (4). Solid osmotic 
agents such as sodium chloride demonstrate similar lumen hydration and steady-state 
TFV release kinetics as glycerol, although the time to steady-state is slightly longer (data 
not shown). Over 95% of the glycerol was released from the IVR in the first 3 days (data 
not shown). Earlier work with higher-molecular-weight water-miscible excipients, such 
as 400-molecular-weight polyethylene glycol, demonstrated a significant ballooning of 
the tubing cross-section upon in vitro and in vivo testing (unpublished work), indicating 
that the swollen effective mesh size of the HPU tested is larger than glycerol but smaller 
than the hydrodynamic radius of polyethylene glycol-400.  
The TFV steady-state release rate increased with the percent swelling of HPU, 
confirming the previous conclusions that TFV is transported predominantly through the 
aqueous phase of the swollen HPU because it is virtually insoluble in the hydrophobic 
polymer phase (4, 12). Equilibrated HPU-B1 IVRs of varying cross-sectional dimensions 
demonstrated steady-state TFV release rates that were in good agreement with the 
predicted values. Altogether, these studies demonstrated the role that HPU swelling, 
tubing cross-sectional dimensions, and HPU elastic modulus play in modulating the TFV 
release rate and ring mechanical properties. 
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5.5.2 Assessment of HPU changed during IVR storage 
Chemical and physical stability studies are often neglected during IVR 
development (14), although significant changes that impact device performance may 
arise as reported herein. The chemical and physical stability of the HPU IVRs was tested 
by placing IVRs at accelerated 40°C storage for various times. Overall, the steady-state 
TFV release rates followed exponential decay kinetics as a function of storage time, 
eventually plateauing. There were no significant changes in the TFV and HPU chemical 
stability after IVR storage, indicating that physical changes to the HPU were responsible 
for the decreased TFV flux. As mentioned above, knowledge concerning the microphase 
separation of polyurethanes has existed for decades (19, 26). However, there has been 
limited work with polyurethanes in drug delivery applications and the effect of 
microphase separation on drug release has not been reported in the literature. 
Furthermore, the chemical composition of polyurethanes is amazingly diverse, as 
isocyanates (i.e., aliphatic or aromatic), chain extenders, polyols (i.e., hydrophobic, 
hydrophilic, or amphiphilic), and the molecular weight and weight fraction of hard/soft 
segments all contribute to the structure-property relationship of polyurethanes (36). As a 
result, it is difficult to compare the resultant physical properties (i.e., microphase 
separation) for compositionally different polyurethanes, especially because most 
literature reports do not utilize commercially available polyurethanes and no studies have 
been reported with Tecophilic commercial HPU grades, much less regarding drug release 
from these polyurethanes. 
The brand name Tecophilic refers to segmented polyether urethanes composed of 
the aliphatic 4,4’-dicyclohexylmethane diisocyanate (H12MDI) and 1,4-butanediol as the 
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hard segment and polytetramethylene oxide (PTMO) and polyethylene oxide (PEO) co-
polymer as the soft segment (35). The physical properties and morphology of H12MDI 
polyurethanes are generally different from polyurethanes utilizing the more common 
aromatic isocyanate methylene diphenyl diisocyanate. In particular, H12MDI hard 
segments are inferior at crystallizing and form smaller amorphous or semicrystalline 
domains (19, 36). Commercially available H12MDI is composed of 30% trans,trans, 65% 
trans,cis, and 5% cis,cis geometric isomers (36). The trans,trans fraction of H12MDI 
influences the degree of crystallinity, as it is the only isomer that can crystallize (27, 38). 
Polyurethane microphase separation kinetics can be very slow, resulting in significant 
time-dependent performance, which may influence not only the mechanical stiffness as 
we have previously reported (5) but also the drug release in a combination drug-device.  
Several techniques have been used extensively to characterize polyurethane 
microphase separation for over four decades, including Fourier transform infrared 
spectroscopy, differential scanning calorimetry, and small-angle x-ray scattering (18, 26). 
These three techniques were utilized in an attempt to characterize any physical changes 
of the HPU as a function of IVR storage time (the IVRs were stored but not hydrated 
prior to testing). However, no significant changes were observed with any technique (data 
not shown) even though large decreases in the steady-state drug release rate were evident. 
The above techniques have primarily been used to monitor the crystallinity of 
crystallizable hard segments, which increases with the extent of microphase separation. 
However, H12MDI polyurethanes exhibit minimal hard segment crystallinity, as 
discussed above.  
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The water molecules present in hydrated hydrophilic polymers have been 
categorized into three different states: bound, partially bound, and free (9). Bound water 
is closely associated with the polymer due to strong hydrogen bonding and does not 
exhibit calorimetric freezing as low as -100°C because its mobility is restricted. Free 
water is able to diffuse because it is only involved in water-water interactions, 
crystallizing at approximately -10 to -20°C and melting at approximately 0°C. Partially 
bound water exhibits both polymer-water and water-water interactions, demonstrating 
intermediate mobility with phase transition temperatures that are lower than those of free 
water but observable by calorimetric methods. Drug release from hydrophilic polymers is 
generally considered to be primarily dependent on the freezable water fraction (partially 
bound and free), which is mobile and able to dissolve and transport the drug (21, 43). 
These previous studies demonstrated a modulation of the drug release rate from PEO-
containing polyurethanes by varying the percent PEO content, which was correlated with 
an increase in the free water fraction. Yui et al. observed free water by DSC at 21 wt% 
and greater bulk swelling, which they attributed to a physical transition from dispersed 
PEO domains in the hard segments and PTMO (thereby consisting primarily of bound 
water) to dispersed hard segments and PTMO domains in a continuous PEO phase 
(thereby creating free and partially bound water via the formation of water clusters) (43). 
The HPUs investigated in this work had aqueous swelling percentages that were 
significantly higher than 21 wt%, and free water was detected in all swelling grades. The 
enthalpy of melting for free water was found to increase linearly with the bulk swelling 
percent from the equilibrated HPU IVRs, in agreement with the literature. However, 
partially bound water was observed in the higher swelling HPU-B2 and HPU-B3 and was 
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not detectable in the lower swelling HPUs, which coincided with a disproportional 
increase in the TFV release rate. These results indicate that both partially bound water 
and free water contribute to the TFV release kinetics. Unstored HPU-B1 IVRs 
demonstrated partially bound water peak areas (peak 2), which decreased with storage 
time and eventually became undetectable when stabilized TFV release rates were 
achieved. Because the partially bound water peak areas and TFV release rates 
demonstrated indistinguishable exponential decay kinetics and the free water enthalpic 
peak areas decreased only slightly with storage time, it appears that the loss in partially 
bound water was primarily responsible for the decreased TFV flux after IVR storage.  
The underlying physical mechanism whereby polyurethane microphase separation 
induces changes in the bulk swelling and water state is uncertain. The solubility 
parameters of PTMO and PEO are quite similar at lower temperatures (i.e., during 
product storage), whereas the solubility parameter of the hard segment differs 
significantly (43). Although Yui et al. did not perform physical stability studies (i.e., 
microphase separation kinetics), they concluded that the PTMO and/or PEO phase 
separate from the hard segments but that it is improbable that PEO and PTMO phase 
separate from each other. We could not discern any change in the soft segment glass 
transition temperature after storage that would suggest that the PEO and PTMO were 
phase separating. However, they likely possess similar glass transition temperatures 
which may be indistinguishable by DSC (32, 43). Therefore, we similarly hypothesize 
that during hot-melt extrusion, the hard segment and soft segment are miscible and form 
a homogenous bulk polymer phase, whereby uniform swelling is achieved with little 
hindrance to the hydration of PEO. However, as a function of cooling and storage time, 
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PEO (and likely PTMO) phase separates from the hard segments, influencing the 
hydration of PEO and the overall mass of water absorbed. In turn, this process decreases 
the total amount of free and partially bound water. Once the microphase separation is 
complete, the HPU is thermodynamically stable, as indicated by no further changes in 
bulk swelling, water state, or TFV release kinetics.  
The percent swelling of HPU immediately following tubing extrusion was 
significantly greater when compared to unextruded polymer pellets. ALZA Corporation 
attempted to reproducibly control the swelling of Tecophilic HPU by subjecting the 
extrudate to elevated temperatures for approximately 48 h (15). Although we found that 
similar time-temperature conditions aided in stabilizing the bulk swelling, it was 
insufficient to fully equilibrate the TFV release rates and the amount of partially bound 
water. In another attempt to stabilize the HPU rate-controlling membranes, Endo 
Pharmaceuticals utilized “priming and conditioning,” whereby devices were immersed in 
aqueous solutions and subsequently packaged to allow HPU hydration (17). Their success 
at achieving stabilized drug release rates after storage was not demonstrated. Also, 
product hydration is an undesirable manufacturing step because the drug may leach out of 
the device during manufacturing and storage and polyurethane hydrolytic degradation is 
probable during storage (36). We thus selected a simple final manufacturing step in 
which the packaged IVRs are stored for approximately 2 weeks at 40°C to bring the 
HPU-B1 to near-equilibrium. 
The presence of glycerol in the IVR formulation complicated the investigation of 
the physical instability. There is evidence that low-molecular-weight alcohols accelerate 
polyurethane microphase separation and impact the polyurethane’s morphology (8). In 
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particular, Meuse et al. showed that glycerol enables polyurethane to achieve a higher 
degree of microphase separation (22). As reported herein, it appears that glycerol 
accelerates the slow microphase separation kinetics in the hot-melt extruded Tecophilic 
polyurethanes via a plasticizing effect because the tubing alone eventually attained the 
same TFV equilibrium release rate but after a significantly longer storage time.  
 
 
5.5.3 In vivo assessment 
The sheep vaginal tract is anatomically similar to the human vaginal tract (41) and 
therefore enables the animal testing of IVR clinical products without needing to alter the 
device dimensions. In vivo, no rings were expelled over the 90 day study and there were 
no adverse histopathological findings (data not shown). Although clinical testing is 
needed to confirm the device performance in women, these pilot results indicate that the 
rings had sufficient mechanical stiffness and critical bend radius to be retained in the 
vaginal tract yet not cause obvious epithelial tissue damage. The mean TFV release rate 
was 75% higher in vivo than in vitro, in agreement with two previous in vivo sheep 
studies with an earlier prototype, where the in vivo release rate was approximately 70% 
higher than in vitro (see Chapter 4). This device therefore released a similar daily amount 
of TFV as that in a previous study, demonstrating that the time-independent in vivo 
vaginal concentrations of TFV were similar to or exceeded the peak concentrations from 
the TFV 1% vaginal gel. A number of potential explanations exist for the higher in vivo 
release rate, with the most likely being increased TFV solubility in the pH 7 sheep 
vaginal fluid than in the pH 4.2 in vitro release medium that was designed to simulate the 
normal acidic vaginal pH of women (25). Because the solubility of TFV increases with 
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increased pH, a higher dissolved TFV concentration in the IVR lumen would establish a 
higher TFV concentration gradient across the tubing wall, increasing the TFV release rate 
as described in Equation 5.1. As a result, studies in women are needed to determine an in 
vivo/in vitro release correlation. However, any necessary adjustment of the steady-state 
TFV release rate can be easily accomplished by changing the HPU equilibrium swelling 
or tubing dimensions, as demonstrated herein.  
The vaginal drug delivery field has not met the need for a cost-effective device 
capable of long-term, controlled delivery of hydrophilic drugs such as TFV. We 
addressed this need by designing and testing a novel HPU tubing IVR that provides zero-
order TFV delivery for up to 90 days. The percent swelling of the HPU and the ring 
geometry were modulated to achieve equilibrated steady-state release rates ranging from 
1 - 30 mg/day, which was approximately 1000-fold greater than other IVR designs 
recently reported (23, 24). We anticipate that the ring design will serve as a versatile 
platform for the vaginal delivery of a variety of therapeutic agents (14). The ring design 
allows for room-temperature, solvent-free manufacturing with drug/excipient loadings up 
to 3 grams and could potentially expand ring delivery to a diverse spectrum of 
therapeutics that cannot withstand typical ring fabrication temperatures or cannot 
adequately diffuse through conventional polymers at the required release rate. Proven 
manufacturing technologies from the medical device field were utilized to ensure that the 
device could be scaled to high-volume manufacturing capacity at a low cost to maximize 
its potential impact in resource-poor regions where such a product is most needed. The 
steady-state drug release rates decreased exponentially when the IVRs were stored at 
40°C, and was primarily attributed to the decreased amount of partially bound water in 
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the hydrated HPU. After equilibration of the HPU, a final device composition and design 
was selected that provided a time-independent ring mechanical stiffness similar to 
marketed rings and TFV release rates of approximately 10 mg/day for 90 days. In vivo, 
the IVRs were well tolerated with no ring expulsions or obvious histopathological 
findings. In summary, a tunable IVR platform was designed and characterized that 
demonstrated elevated and zero-order TFV delivery, offering an alternative dosage form 
to the TFV 1% gel that is controlled and long-lasting.  
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Table 5.1. IVR formulation matrix. 
 
IVR ID Polymer Wall thickness evaluated (mm) 
HPU-35 * HP-60D-35 0.68 
HPU-60 HP-60D-60 0.68 
HPU-B1 75/25 HP-60D-60/HP-93A-100 0.68, 0.87, 1.02, 1.21 
HPU-B2 50/50 HP-60D-60/HP-93A-100 0.68 
HPU-B3 25/75 HP-60D-60/HP-93A-100 0.68 
* HPU-35 IVRs with cores containing 100% TFV and 65/33/2 wt% TFV/glycerol/water 
























Table 5.2. HPU-B1 molecular weight as a function of 40°C IVR storage time. Mean of 3 
measurements.  
 
Time (weeks) Mn (kDa) Mw (kDa) PDI 
0 51 127 2.5 
2 44 110 2.5 




















Table 5.3. The bulk swelling and enthalpic water peak areas of the hydrated HPU-B1 
IVRs as a function of 40°C storage time. Mean ± SD, N = 3 IVRs. The peak area is 










-ΔH peak 1 
(J/g) 
-ΔH peak 2 
(J/g) 
ΔH peak 4 
(J/g) 
0 69.4 ± 0.9 65.2 ± 0.6 12.5 ± 2.5 24.6 ± 1.2 29.6 ± 2.0 
1 64.1 ± 0.3 59.8 ± 0.1 5.7 ± 1.3 7.8 ± 1.0 22.9 ± 0.4 
2 60.7 ± 0.4 57.2 ± 0.1 5.9 ± 2.0 2.2 ± 0.2 20.9 ± 2.6 
4 60.5 ± 0.3 56.7 ± 0.1 6.6 ± 0.5 1.2 ± 1.1 22.5 ± 1.4 
6 58.6 ± 1.0 55.8 ± 1.0 4.2 ± 0.9 ND 16.7 ± 1.1 























Table 5.4. The enthalpic water peak areas of the hydrated and equilibrated HPU IVRs. 
Mean ± SD, N = 3 IVRs. The peak area is expressed as joules per gram of dry polymer. 
ND: not detectable. 
 
Polymer -ΔH peak 1 (J/g) -ΔH peak 2 (J/g) ΔH peak 4 (J/g) 
HPU-35 3.3 ± 1.6 ND 9.7 ± 0.8 
HPU-60 2.7 ± 0.8 ND 15.3 ± 0.4 
HPU-B1 6.7 ± 1.1 ND 19.4 ± 1.8 
HPU-B2 9.4 ± 0.6 16.3 ± 3.2 24.9 ± 1.3 































Figure 5.2. The theoretical critical bend radius as a function of tubing wall thickness and 
cross-sectional diameter. At tubing bend radii below and above the curved surface (i.e., 
below and above the critical bend radius), the tubing will and will not be kinked, 










Figure 5.3. (A) In vitro TFV release rate as a function of time for unstored HPU-35 IVRs 
with and without glycerol in the tubing lumen (mean ± SD, N = 3 IVRs). (B) Steady-state 
TFV release rate as a function of 40°C storage time for IVRs fabricated from HPU-B1, 







Figure 5.4. (A) Representative DSC cooling and heating curves of hydrated HPU-B1 
IVRs before and after IVR 40°C storage. Peaks 1 and 2 represent the freezing point for 
free and partially bound water, respectively, whereas peaks 3 and 4 represent the melting 
point for partially bound and free water, respectively. (B) Enthalpy of freezing for 
partially bound water (peak 2) as a function of 40°C storage time (mean ± SD, N = 3 






Figure 5.5. (A) Equilibrium TFV release rate as a function of the equilibrium swelling of 
HPU (mean ± SD, N = 3 IVRs, release rates averaged over days 5-14). (B) Enthalpy of 
melting for free water (peak 4) as a function of equilibrium swelling of HPU at 20°C 

















Figure 5.6. Predicted and measured equilibrium TFV release rate as a function of ln(ro/ri) 

















Figure 5.7. Predicted and measured 10% force compression values as a function of the 
IVR wall thickness for unfilled HPU-B1 IVRs (mean ± SD, N = 3 IVRs, release rates 











Figure 5.8. (A) TFV release rate and (B) force required for 10% ring compression as a 
function of time for HPU-B1 IVRs stored for 2 weeks at 40°C (mean ± SD, N = 3 IVRs). 
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The aim of the work presented in this dissertation was to advance the microbicide 
IVR field by 1) designing and testing new IVR constructs in which to deliver promising 
antiretroviral candidates, and 2) increasing the understanding of microbicide IVR 
performance through new safety and pharmacokinetic animal models. Overall, this 
dissertation work resulted in new IVR platforms which successfully formulated several 
diverse antiretrovirals. Furthermore, this work increased the understanding of IVR device 
design and corresponding in vivo safety, vaginal biodistribution, and pharmacokinetics 
through the development of new animal models. The most recent work with the TFV 
reservoir IVR resulted in the filing of a patent application as well as the scheduling of a 
phase one clinical trial in early 2013.  
In the following sections, brief conclusions from each chapter will be discussed, 
followed by recommendations for future research in the microbicide IVR field. 
 
 
6.1 Chapter Conclusions 
6.1.1 Chapter 2 
In Chapter 2 we developed an IVR formulation to deliver the promising small 
molecule pyrimidinediones which possess nanomolar HIV-1 reverse transcriptase and 
entry inhibition. Since only a handful of in vivo microbicide IVR studies had been 
reported at the time of publication, a dose-finding study in the pigtail macaque monkey 
model was performed to determine an IVR drug loading, corresponding vaginal 
concentrations and pharmacokinetics, and any effects on the vaginal environment.  Major 
conclusions from this chapter are:  
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1) Nonswellable polyurethanes are an excellent delivery vehicle for hydrophobic 
small molecules including the pyrimidinediones which are highly soluble in the 
polymer and thus can establish loading-dependent release rates. 
2) Nonsink in vitro release conditions accurately predicted the amount of drug 
released in vivo whereas sink conditions over-estimated in vivo release. This in 
vitro testing approach may prove relevant for future IVR research of hydrophobic 
drugs where drug dissolution into the vaginal fluid is likely the rate-limiting step.  
3) The 14 wt% pyrimidinedione IVR achieved drug concentrations approximately 
1000 times the in vitro EC50 throughout the vaginal tract over the 28-day period, 
but caused no obvious vaginal irritation, inflammation, or toxicity as indicated by 
colposcopies, vaginal microflora levels, and vaginal and systemic cytokine levels. 
 
 
6.1.2 Chapter 3 
In Chapter 3 a dual delivery IVR was developed for the two antiretrovirals 
dapivirine and tenofovir which display different mechanisms of viral inhibition. Due to 
their contrasting hydrophilicity, we engineered a multisegment polyurethane ring to 
optimize release of both drugs wherein dapivirine and tenofovir were delivered from 
nonwater swellable and water swellable polyurethane segments, respectively. Major 
conclusions from this chapter are: 
1) Water-swellable polyurethanes provide significantly greater TFV flux than 
hydrophobic polymers conventionally used for IVR formulation. 
2) Both antiretrovirals were chemically stable in the multisegment IVR and were 
released at in vitro concentrations expected to be effective against HIV.  
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3) The ring technology may be useful for other multidrug delivery applications since 
adjusting the polyurethane hard/soft segment ratio, chemical composition, degree 
of hydrophilicity, and length of each segment can all modulate drug release rate. 
 
 
6.1.3 Chapter 4 
In Chapter 4 we designed and tested a new reservoir IVR platform to address 
limitations of the TFV matrix IVR reported in Chapter 3. IVRs were made from 
hydrophilic polyurethane tubing of various equilibrium swelling and tested in vitro and in 
a new sheep model for up to 90 days.  Major conclusions from this chapter are: 
1) A semisolid tubing lumen incorporating TFV and the water-miscible and 
membrane-permeable small molecule glycerol enabled rapid equilibration of drug 
release kinetics and time-independent IVR mechanical stiffness. 
2) Hydrophilic polyurethane tubing IVRs demonstrated zero order TFV release rates 
in vitro for up to 90 days which increased with polymer percent swelling. 
3) TFV vaginal and systemic concentrations in sheep were near time-independent for 
90 days, and were similar to peak concentrations attained with the short duration 
but clinically effective TFV 1% vaginal gel.  
4) Toxicological evaluation indicated that the IVRs were well tolerated for 90 days 
in sheep, although slight vaginal mucosal irritation was observed. 
 
 
6.1.4 Chapter 5 
In Chapter 5 we further designed and characterized a TFV reservoir IVR. IVRs of 
varying equilibrium swelling and tubing wall thickness were studied for their effect on in 
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vitro TFV release kinetics and ring mechanical properties, and chemical and physical 
stability studies were also performed. Major conclusions from this chapter are: 
1) As anticipated, TFV release rates and ring mechanical properties were modulated 
by varying HPU equilibrium swelling, HPU shore hardness, and/or IVR 
dimensions. TFV release rates were also dependent on the amount of free and 
partially bound water as determined by differential scanning calorimetry. IVRs 
were tested in vitro that delivered 1 to 30 mg/day of TFV in a zero order fashion 
for up to 90 days with time-independent mechanical stiffness. 
2) Physical stability testing (i.e., shelf-life experiments) revealed that polyurethane 
microphase separation occurred over weeks to months at 40°C, resulting in 
decreased TFV flux through the hydrated polymer due to decreased bulk swelling 
and the amount of partially bound water. 
3) Time to polymer equilibration (i.e., complete microphase separation) increased 
with polymer shore hardness (elastic modulus). Storing the final formulation for 2 
weeks at 40°C brought the ring to near-equilibrium, whereby further storage did 
not significantly decrease TFV flux or the state of water in the hydrated polymer. 
4) The versatile IVR platform may be useful for delivering a wide variety of 
therapeutics such as biologics and macromolecules which up to now have lacked 
a sustained vaginal delivery vehicle. 
 
 
6.2 Challenges and Future Directions 
In the last several years, intravaginal rings for HIV prophylaxis have undergone 
significant technological advances and the overall understanding of their in vivo 
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performance has deepened. However, there are still many hurdles and unknowns that 
need to be resolved relating in part to early formulation work, target product profile, drug 
selection, dosage duration, multi-drug combinations, and vaginal biodistribution and 
pharmacodynamics. In the following section, major challenges and unknowns related to 
microbicide IVR development will be discussed as well as proposed future directions and 
priorities to ensure that an effective microbicide IVR product becomes readily available 
and implemented in the fight against HIV.  
The academic drug delivery community often conveniently overlooks practical 
issues such as API chemical and physical stability, cost and reproducibility, and 
manufacturability, all of which must be seriously considered when designing drug 
delivery devices for use in the developing world. The majority of HIV infected 
individuals reside in resource-poor regions of the world, demanding the need for 
prophylactic devices at a reasonable price point for their region (6). For example, a 10 
USD intravaginal ring is considered extremely cost effective in North America but is 
simply too costly to reach a significant market in the developing world, where a price of 
approx. 0.50 USD would be a significant expenditure for many if not most users. 
Complicated systems necessarily may be more desirable, if and only if they measurably 
perform better than simple devices, show chemical and physical stability, and also meet 
cost requirements while being made with modern pharmaceutical manufacturing 
equipment. Weighing these considerations is essential at project initiation to ensure the 




As the microbicide field is still emerging with only a handful of clinically 
evaluated products and only one shown to be clinically effective (1), target product 
profiles are often vague or even disputed throughout the field. For example, we do not 
have any design rules for prioritizing the need for time independent drug release versus 
release that changes with time. Typically, the drug delivery field prefers time-
independent release as it threads the needle for products with a narrow therapeutic 
window between side effects and ineffectiveness. However, a rapid burst or pulsatile 
release followed by a lower maintenance dose may be sufficient or even advantageous to 
load up drug in the vaginal tissue and provide near instantaneous protection after 
insertion. With the proven anti-HIV activity of small molecules used in highly-active 
anti-retroviral therapies, the microbicide field has generally taken the approach of “the 
more the better” since little or no side effects have been observed with these small 
molecules as vaginal microbicides and the vaginal dose attained is significantly less than 
the oral administration route. Conversely, the long-term effect of locally high 
concentrations on tissue toxicity or emergence of drug-resistant virus is not known, and 
the goal of attaining “zero” drug in plasma but “as high as possible” drug in vaginal fluid 
and tissue is not realistic.  
API selection is another important microbicide product consideration, although 
pharmaceutical company licensing rights often dictate what APIs move forward for 
microbicide development. API vaginal and/or intracellular half-life, chemical and 
physical stability, potency, and aqueous and polymer solubility should all be considered 
and contrasted before moving forward with IVR formulation studies. Target dosage 
duration is yet another unknown – contraceptive IVRs available currently range from 3 
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weeks to 1 year duration (2). The primary argument for longer duration is to amortize 
IVR costs and make the product more affordable, and therefore microbicide IVRs are 
generally designed for a 1 to 3 month duration (3). The impact of IVR duration on user 
acceptability, device performance, and biocompatibility has not been comprehensively 
reported and is worth further evaluation. For example, the user acceptability and 
willingness to continue using an IVR that is discolored from blood discharge during 
menses is not known.  
Currently, there is significant interest in developing combination IVRs that 
incorporate multiple antiretrovirals with different mechanisms of HIV inhibition to 
prevent selection of drug-resistant virus (4, 5). Although this rationale is logical, upon 
conclusion of the CAPRISA 004 tenofovir vaginal gel clinical trial there were no 
tenofovir-resistant virus detected in women who contracted the virus while using the gel 
(1). As regulatory hurdles, formulation complexity, and cost become significantly greater 
with the incorporation of additional APIs, the necessity of such multi-API formulations 
should be clinically established. As discussed above, device complexity, 
manufacturability, and cost play a crucial yet undefined role in the probability of a device 
being readily available and affordable to the resource-poor regions most in need of HIV 
prevention technologies. Often, a compromise between achieving target device 
performance criteria (i.e., time-independent release or device duration) and device cost 
and manufacturability may be necessary.  
Another variable often not considered is the effect of menstrual cycle variation 
and sexual intercourse on drug release from an IVR. In cases where the flux of a drug 
from the IVR surface is limited by its solubility in the surrounding fluid, it is conceivable 
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that changes in the vaginal environment could affect drug release. For instance, drug 
release could be reduced in the case of peri-menopausal vaginal dryness, or increased 
upon the introduction of semen to the insertion site due to changes in the available 
dilution volume. The increase in vaginal pH following intercourse could also result in a 
temporary modulation of the release rate of drugs which exhibit pH-dependent aqueous 
solubility. Some IVR dosing regimens currently under consideration involve the user 
leaving the ring in place for one or more menstrual cycles. During this time drug release 
rates could be modulated by the composition of the vaginal fluid which may contain 
various drug-solubilizing factors such as hemoglobin as well as by an increase in the 
vaginal fluid volume as already mentioned. 
As we look ahead to the many challenges facing microbicide IVR development 
we provide our thoughts as to where future efforts should be focused. The first and most 
dire need, especially given the results of the VOICE trial, is the need for independent 
(nonuser reported) measures of adherence to IVR dosage forms. A quantitative 
technology that can tell clinicians if and when a participant used the IVR device as 
instructed will be critical in interpreting prevention trial results and in pointing the way 
forward if they succeed or fail. Without this information the cause of negative clinical 
outcomes will continue to be uncertain, and the field can only postulate whether 
ineffectiveness was due to low adherence, an inefficacious product, or some combination 
of both. Next, the microbicide field needs to significantly better its understanding of in 
vivo pharmacokinetics, vaginal biodistribution and safety and how they relate to efficacy. 
This is the interdisciplinary junction where drug delivery, immunology, virology, and 
pharmacokinetics and pharmacodynamics, come together. Expert teams in these areas 
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need to collaborate with primatologists and clinicians to address these important 
questions. Increased utilization of animal models at an early stage in IVR formulation 
development will avoid progressing IVR systems without knowing detailed 
pharmacokinetics and efficacy, and before spending rare resources on developing an 
IND, producing clinical supplies, and conducting clinical trials. Employing these pilot 
animal studies, specific drug delivery performance criteria (e.g., target in vivo release rate 
or vaginal tissue concentration) could then be established early on to guide device design 
or decide between multiple IVR formulations.  
The microbicide IVR field also needs in-depth IVR acceptability studies - where 
women actually insert and wear IVRs - to provide feedback on IVR design variables such 
as ring dimensions, stiffness, color, and dosage duration. Clearly, acceptability and 
adherence are the Achilles’ heel of microbicide vaginal gels, and demonstrating 
improvement of both with an IVR is of utmost importance to give hope for an effective 
microbicide IVR. IVR dimensions and stiffness are often neglected during early IVR 
development although several marketed and clinically evaluated rings are known to have 
significant vaginal expulsion rates. The rationale for microbicide IVR product duration 
(proposed to range from days to years) is often not explained well, but critical factors 
considered should include pharmacokinetics/API release rate, cost, safety, and perhaps 
most importantly acceptability and adherence. 
With rapidly emerging macromolecules and biologics possessing microbicide 
potential, developing suitable yet cost-effective IVR delivery systems is a considerable 
challenge as conventional IVR designs are inadequate. Achieving greater IVR capability 
and sophistication with innovative designs does not necessarily denote increased costs, 
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yet cost must be regarded since an effective yet expensive microbicide may never reach 
the intended users. Similarly, polymer IVR selection should be considered upon project 
initiation so as to avoid potential supply issues in clinical trials and beyond. 
Encouragingly, pharmaceutical companies are becoming more willing to offer anti-HIV 
APIs for microbicide applications, and as more APIs become available a screening and 
selection process should be in place to accelerate IVR formulation for the most promising 
APIs so as to not waste time and resources.  
Intravaginal ring technology for microbicide applications has progressed 
significantly during the last decade. A wide variety of exciting new ring designs show 
considerable promise for controlled and sustained vaginal delivery of multiple APIs 
including small molecules, biologics, and synthetic macromolecules. These advances 
were driven by the international attention and funding directed to the problem of HIV 
prophylaxis in women.   Although incomplete, our understanding of critical device design 
and performance deepened, and is evident in numerous new IVRs currently in 
development and under clinical evaluation. Furthermore we are already seeing these 
technologies disseminate into diverse indications such as vaccines, contraception, 
menopause and chemotherapy that together show great promise in the often overlooked 
area of women’s health. The accelerating development and utilization of animal models 
for IVR safety and drug pharmacokinetic evaluation has helped broaden our 
understanding of the relationship of IVR device design and in vivo performance. Non-
human primate models will continue to play an increased role in designing, 
characterizing, and screening IVR products prior to clinical trials. The effectiveness 
demonstrated in the CAPRISA 004 clinical trial with the tenofovir vaginal gel is recent 
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proof of progress in HIV prevention science and offers hope backed by solid clinical 
science for new and improved technologies and methodologies to reduce HIV 
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